	Weeks	Daily dose	Niaspan FCT dosage

Initial titration schedule	0 to 4	500 mg	One 500 mg tablet at bedtime

5 to 8	1,000 mg	One 1,000 mg tablet or two 500 mg tablets at bedtime

9 to 12	1,500 mg	One 1,000 mg tablet and one 500 mg tablet at bedtime

13 to 24	2,000 mg	Two 1,000 mg tablets at bedtime

	Weeks	Daily dose	Niaspan FCT dosage

Initial titration schedule	13 to 24	2,000 mg	Two 1,000 mg tablets at bedtime


 	Group I(n = 25)	Group P(n = 25)	P value

Desaturation (SpO2 < 90%)	3 (12%)	2 (8%)	1.000

Gastric insufflations	1 (4%)	0 (0%)	1.000

Aspiration	0 (0%)	0 (0%)	—

Laryngospasm	1 (4%)	1 (4%)	1.000

Bronchospasm	0 (0%)	0 (0%)	—

Blood stain	0 (0%)	2 (8%)	0.490

	Group I(n = 25)	Group P(n = 25)	P value

Bronchospasm	0 (0%)	0 (0%)	—

Blood stain	0 (0%)	2 (8%)	0.490


Remaining per-base coverage after B-tail removal	Number of positions with this coverage in the ZR reference (Bv-95nt data)	Number of positions with this coverage in the PhiX reference (PhiX-95nt data)

90 to 100%	41,130 (40.26%)	4,016 (91.65%)

80 to 90%	4,056 (3.97%)	266 (6.07%)

60 to 80%	1,711 (1.67%)	100 (2.28%)

40 to 60%	310 (0.30%)	0 (0.00%)

20 to 40%	76 (0.07%)	0 (0.00%)

0 to 20%	29 (0.03%)	0 (0.00%)

Remaining per-base coverage after B-tail removal	Number of positions with this coverage in the ZR reference (Bv-95nt data)

90 to 100%	41,130 (40.26%)

80 to 90%	4,056 (3.97%)

60 to 80%	1,711 (1.67%)

40 to 60%	310 (0.30%)

20 to 40%	76 (0.07%)

0 to 20%	29 (0.03%)


Medical categories	Number of species	Citations	Fic

Tonic	5	38	0.89

Dermatological	4	120	0.97

Gastrointestinal	32	433	0.92

Galactagogue	8	86	0.91

Reproductive	11	155	0.93

Miscellaneous	22	201	0.89

Respiratory disorders	4	37	0.91

Fever	5	41	0.90

Wound healing	7	41	0.85

Medical categories	Number of species	Citations

Tonic	5	38

Dermatological	4	120

Gastrointestinal	32	433

Galactagogue	8	86

Reproductive	11	155

Miscellaneous	22	201

Respiratory disorders	4	37

Fever	5	41

Wound healing	7	41


Marker	Peripheral stroma	Central stroma	Anterior stroma	Posterior stroma

ABCG2	−	−	−	−

ABCG5	−	−	−	−

ALDH1A1	++	++	++	+

α-Actinin	++	++	++	+

CD31	+	+	+	+

CD34	++	++	++	++

CD73	−	−	−	−

CD90	−	−	−	−

CD105	−	−	−	−

Collagen I	++	++	++	++

Collagen IV	−	−	−	−

CXCR4	−	−	−	−

Fibroblast marker	−	−	−	−

Fibronectin	−	−	−	−

Ki-67	−	−	−	−

Nestin	−	−	−	−

VE-Cadherin	−	−	−	−

Vimentin	++	++	++	++


Axis	CoG Position	Linear Acceleration

First Version	Second Version	First Version	Second Version

X	2.4252e−06	1.0008e−06	--*	--*

Y	1.3992e−05	1.3390e−05	6.3191e−06	5.1146e−06

Z	1.5306e−05	4.4980e−06	2.7849e−06	2.3104e−06

Axi	CoG Position	Linear Acceleration

First Version	Second Version	First Version	Second Version


	Over-expressed in melan-a v B16	Under-expressed in melan-a v B16	Total

Upregulated by RA treatment	71	14	85

Downregulated by RA treatment	16	132	151

Total	87	149	233


Group	Variable	Lambda	F	DF1	DF2	p-value

SD-Risk	IFN	0.4841	17.5871	2	33	< 0.0001


line	gene copy number

WT	0

Sox23	6 (12 homozygous)

Sox42	1 (2 homozygous)

Sox44	2 (4 homozygous)

gene copy number

0

6 (12 homozygous)

1 (2 homozygous)

2 (4 homozygous)


Skill 1	Skill 2	Skill 3	Skill 4	Skill 5	Total/Avg	Skill 6


Index	Placebo group	Zaleplon 10 mg group	Zaleplon 15 mg group

Scores of SQS	3.75 ± 1.04	5.38 ± 0.92**	6.00 ± 0.76**

Scores of SDS	3.25 ± 1.04	4.62 ± 1.41*	6.12 ± 0.83**∆

Scores of SSS	2.38 ± 0.92	2.12 ± 0.64	2.38 ± 0.92

Index	Placebo group	Zaleplon 10 mg group	Zaleplon 15 mg group

Scores of SDS	3.25 ± 1.04	4.62 ± 1.41*	6.12 ± 0.83**∆

Scores of SSS	2.38 ± 0.92	2.12 ± 0.64	2.38 ± 0.92


Characteristic	No. of patients	%

Patients evaluable	40	100

Age, years

 Median	65

 Range	34–75

Sex

 Male	24	60

 Female	16	40

ECOG PS

 0	6	15

 1	27	67.5

 2	7	17.5

Disease location

 Gastric	30	75

 GEJ	10	25

Histologic type

 Diffuse	19	47.5

 Intestinal	15	37.5

 Unspecified	6	15

Previous adjuvant chemotherapy	6	15

Status of primary tumor

 Unresected	28	70

 Resected	12	30

Predominant site of disease

 Liver	24	60

 Peritoneum	8	20

 Nodes	4	10

 Lung	2	5

 Bone	2	5

No. of metastatic sites

 1	11	27.5

 2	19	47.5

 ≥ 3	10	25

Characteristic	No. of patients	%

Male	24	60

Female	16	40

ECOG PS

0	6	15

1	27	67.5

2	7	17.5

Disease location

Gastric	30	75

GEJ	10	25

Histologic type

Diffuse	19	47.5

Intestinal	15	37.5

Unspecified	6	15

Previous adjuvant chemotherapy	6	15

Status of primary tumor

Unresected	28	70

Resected	12	30

Predominant site of disease

Liver	24	60

Peritoneum	8	20

Nodes	4	10

Lung	2	5

Bone	2	5

No. of metastatic sites

1	11	27.5

2	19	47.5

≥ 3	10	25


Patient	Karyotype/Molecular lesion(s)	FAB subgroup	Age at diagnosis	IDO1 status	CR	Relapse	Alive

UPN #1	Normal	M2	13.0	Negative	Yes	No	Yes

UPN #2	t(8;21) (q22;q22)	M2	13.0	Negative	Yes	No	Yes

UPN #3	Normal	M1	10.0	Negative	Yes	No	Yes

UPN #4	Normal	M2	4.9	Negative	Yes	No	Yes

UPN #5	Normal	M5	12.0	Negative	Yes	No	Yes

UPN #6	Normal	M1	3.0	Negative	Yes	No	Yes

UPN #7	t(8;21) (q22;q22)	M2	9.0	Negative	Yes	No	Yes

UPN #8	Normal	M1/M2	1.0	Negative	Yes	No	Yes

UPN #9	Normal	M2	15.0	Negative	Yes	No	Yes

UPN #10	N.A.	M1	15.4	Negative	No	Yes	No

UPN #11	Normal	N.A.	N.A.	Negative	No	Yes	No

UPN #12	FLT3-ITD	U	6.0	Negative	No	Yes	Yes

UPN #13	Normal	M2	3.4	Negative	Yes	Yes	Yes

UPN #14	t(6;9) - FLT3-ITD	M4	23.0	Negative	Yes	Yes	No

UPN #15	Normal	M5	15.5	Negative	Yes	Yes	No

UPN #16	t(8;21) (q22;q22)	M2	11.3	Negative	Yes	Yes	Yes

UPN #17	t(8;21) (q22;q22)	M2	9.0	Negative	Yes	Yes	No

UPN #18	FLT3-ITD	N.A.	14.0	Negative	N.A.	Yes	No

UPN #19	t(9;11)(p22;q23) - MLL-AF9	M5	1.0	Positive	No	No	No

UPN #20	t(10;11) - MLL-AF10	M5	6.0	Positive	Yes	No	Yes

UPN #21	inv(16)(p13q22)	M4	16.0	Positive	Yes	No	No

UPN #22	t(8;21) (q22;q22)	M4	16.0	Positive	Yes	No	Yes

UPN #23	t(10;11) - MLL-AF10	M4/M5	4.0	Positive	Yes	No	Yes

UPN #24	FLT3-ITD	M4	12.3	Positive	Yes	No	Yes

UPN #25	inv(16) (p13q22)	M4	17.2	Positive	Yes	No	Yes

UPN #26	t(1;11) - MLL-AF1	M5	0.2	Positive	Yes	No	Yes

UPN #27	inv(16)(p13q22)	M5	9.0	Positive	Yes	No	Yes

UPN #28	Normal	M5	16.5	Positive	N.A.	No	No

UPN #29	FLT3-ITD	M5	7.0	Positive	No	Yes	No

UPN #30	Normal	M5	14.1	Positive	Yes	Yes	No

UPN #31	FLT3-ITD	M5	15.0	Positive	Yes	Yes	No

UPN #32	Normal	M5	0.4	Positive	Yes	Yes	Yes

UPN #33	FLT3-ITD	M5	12.3	Positive	Yes	Yes	No

UPN #34	inv(16) (p13q22)	M4	13.0	Positive	Yes	Yes	Yes

UPN #35	t(10;11) - MLL-AF10	M5	4.0	Positive	Yes	Yes	No

UPN #36	inv(16) (p13q22)	M4	0.8	Positive	Yes	Yes	Yes

UPN #37	FLT3-ITD	M4	15.7	Positive	N.A.	Yes	No

Patient	Karyotype/Molecular lesion(s)

UPN #1	Normal

UPN #2	t(8;21) (q22;q22)

UPN #3	Normal

UPN #4	Normal

UPN #5	Normal

UPN #6	Normal

UPN #7	t(8;21) (q22;q22)

UPN #8	Normal

UPN #9	Normal

UPN #10	N.A.

UPN #11	Normal

UPN #12	FLT3-ITD

UPN #13	Normal

UPN #14	t(6;9) - FLT3-ITD

UPN #15	Normal

UPN #16	t(8;21) (q22;q22)

UPN #17	t(8;21) (q22;q22)

UPN #18	FLT3-ITD

UPN #19	t(9;11)(p22;q23) - MLL-AF9

UPN #20	t(10;11) - MLL-AF10

UPN #21	inv(16)(p13q22)

UPN #22	t(8;21) (q22;q22)

UPN #23	t(10;11) - MLL-AF10

UPN #24	FLT3-ITD

UPN #25	inv(16) (p13q22)

UPN #26	t(1;11) - MLL-AF1

UPN #27	inv(16)(p13q22)

UPN #28	Normal

UPN #29	FLT3-ITD

UPN #30	Normal

UPN #31	FLT3-ITD

UPN #32	Normal

UPN #33	FLT3-ITD

UPN #34	inv(16) (p13q22)

UPN #35	t(10;11) - MLL-AF10

UPN #36	inv(16) (p13q22)

UPN #37	FLT3-ITD

FAB subgroup	Age at diagnosis	IDO1 status	CR	Relapse	Alive

M2	13.0	Negative	Yes	No	Yes

M2	13.0	Negative	Yes	No	Yes

M1	10.0	Negative	Yes	No	Yes

M2	4.9	Negative	Yes	No	Yes

M5	12.0	Negative	Yes	No	Yes

M1	3.0	Negative	Yes	No	Yes

M2	9.0	Negative	Yes	No	Yes

M1/M2	1.0	Negative	Yes	No	Yes

M2	15.0	Negative	Yes	No	Yes

M1	15.4	Negative	No	Yes	No

N.A.	N.A.	Negative	No	Yes	No

U	6.0	Negative	No	Yes	Yes

M2	3.4	Negative	Yes	Yes	Yes

M4	23.0	Negative	Yes	Yes	No

M5	15.5	Negative	Yes	Yes	No

M2	11.3	Negative	Yes	Yes	Yes

M2	9.0	Negative	Yes	Yes	No

N.A.	14.0	Negative	N.A.	Yes	No

M5	1.0	Positive	No	No	No

M5	6.0	Positive	Yes	No	Yes

M4	16.0	Positive	Yes	No	No

M4	16.0	Positive	Yes	No	Yes

M4/M5	4.0	Positive	Yes	No	Yes

M4	12.3	Positive	Yes	No	Yes

M4	17.2	Positive	Yes	No	Yes

M5	0.2	Positive	Yes	No	Yes

M5	9.0	Positive	Yes	No	Yes

M5	16.5	Positive	N.A.	No	No

M5	7.0	Positive	No	Yes	No

M5	14.1	Positive	Yes	Yes	No

M5	15.0	Positive	Yes	Yes	No

M5	0.4	Positive	Yes	Yes	Yes

M5	12.3	Positive	Yes	Yes	No

M4	13.0	Positive	Yes	Yes	Yes

M5	4.0	Positive	Yes	Yes	No

M4	0.8	Positive	Yes	Yes	Yes

M4	15.7	Positive	N.A.	Yes	No


Concentration range (pg/g lipid)	Second-order (equivalent to minus change in apparent elimination rate in 2006)	First-order (equivalent to minus apparent elimination rate)

coefficient	p-value	coefficient	p-value

0–10	−0.000596	0.599665	−0.004032	0.165814

10–20	0.000464	0.463854	−0.000462	0.786707

Concentration range (pg/g lipid)	Second-order (equivalent to minus change in apparent elimination rate in 2006)	First-order (equivalent to minus apparent elimination rate)

coefficient	p-value	coefficient	p-value

20–50	0.000643	0.182574	0.001669	0.229181

50–100	0.002124	7.99 × 10−5	−0.005452	0.000216

>100	0.001436	9.68 × 10−7	−0.008294	<2 × 10−16


N = 1352	Non-responders n = 909	Responders n = 443	p value

Women, n (%)	520 (57)	273 (62)	0.12 A

Age, average years (SD)	41.3 (11.8)	44.4 (10.8)	0.05 B

Work n (%)			0.15 A

Farming, fishery, industry	150 (17)	65 (15)

Construction, trading and transport	231 (25)	109 (25)

Communication, information, finance, insurance, real estate and consultancy	103 (11)	49 (11)

Public administration, teaching, health, culture and leisure	329 (36)	189 (43)

Other	36 (4)	11 (2)

Missing	60 (7)	20 (5)

Self-reported reason for sickness absence n (%)			<0.001 A

Musculoskeletal disorder (MSD)	387 (43)	244 (55)

Common mental disorder (CMD)	294 (32)	94 (21)

Stress	95 (19)	52 (12)

Functional somatic syndrome/unknown	19 (2)	10 (2)

Heart disorder, lung disorder, cancer	36 (4)	12 (3)

Other	78 (9)	31 (7)

Previous year before inclusion median (iqr)

Employment or unemployment, weeks	42 (26-46)	42 (33-45)	0.35 C

Duration of sickness absence, weeks	7 (5-12)	7 (6-11)	0.43 C

Health care utilization

Visits in general practice	11 (7-18)	12 (7-18)	0.30 C

Visits in physiotherapist clinics	0 (0-0)	0 (0-1)	0.30 C

Visits in out-patient clinics	2 (1-6)	3 (1-6)	0.58 C

Visits in psychiatric out-patient clinics	0 (0-0)	0 (0-0)	0.19 C

Admissions in hospitals	0 (0-0)	0 (0-0)	0.45 C

Admissions in psychiatric hospitals	0 (0-0)	0 (0-0)	0.02 C

One year after inclusion

Labour market participation n (%)			0.92 A

Non-RTW	309 (34)	146 (33)

RTW	548 (60)	273 (62)

Old age and disability pension	50 (6)	22 (5)

Died	2 (0)	2 (0)

N = 1352	Non-responders n = 909	Responders n = 443

Non-RTW	309 (34)	146 (33)

RTW	548 (60)	273 (62)

Old age and disability pension	50 (6)	22 (5)

Died	2 (0)	2 (0)


	Perianal disease prior to pregnancy n = 27	No perianal disease prior to pregnancy n = 87

Mode of childbirth	Vaginal delivery n (%)	Caesarean section n (%)	Vaginal delivery n (%)	Caesarean section n (%)

	11 (41)	16 (59)	66 (76)	21 (24)

Progression perianal disease ≤ 2 years post partum:	2 (18)	5 (31)	3 (5)	3 (14)

 - Yes	9 (82)	9 (56)	58(94)	18 (86)

 - No	0 (0)	2 (13)	5 (1)	0 (0)

 - Not applicable†


Peptide	Sequence	Mw	pI1	Net charge	Mean hydrophobicity2

KHN20	KHNLGHGHKHERDQGHGHQR	2365.5	9.99	+2	−4.91

GHG20	GHGLGHGHEQQHGLGHGHKF	2127.2	7.21	0	−2.01

GHG21	GHGHKFKLDDDLEHQGGHVLD	2354.5	5.63	−3	−2.32

GGH20	GGHVLDHGHKHKHGHGHGKH	2169.3	9.70	+2	−3.44

HKH20	HKHGHGHGKHKNKGKKNGKH	2151.5	10.78	+7	−5.91

GKH17	GKHKNKGKKNGKHNGWK	1946	10.78	+7	−5.77

GKH17WWW	GKHKNKGKKNGKHNGWKWWW	2505	10.78	+7	−3.45

GKH17WWWWW	GKHKNKGKKNGKHNGWKWWWWW	2287	10.78	+7	−2.25

LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	4492	10.61	+6	−1.84

Histatin-5	DSHAKRHHGYKRKFHEKHHSHRGY	3036	10.28	+5	−4.67

Peptide	Sequence	Mw

KHN20	KHNLGHGHKHERDQGHGHQR	2365.5

GHG20	GHGLGHGHEQQHGLGHGHKF	2127.2

GHG21	GHGHKFKLDDDLEHQGGHVLD	2354.5

GGH20	GGHVLDHGHKHKHGHGHGKH	2169.3

HKH20	HKHGHGHGKHKNKGKKNGKH	2151.5

GKH17	GKHKNKGKKNGKHNGWK	1946

GKH17WWW	GKHKNKGKKNGKHNGWKWWW	2505

GKH17WWWWW	GKHKNKGKKNGKHNGWKWWWWW	2287

LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	4492

Histatin-5	DSHAKRHHGYKRKFHEKHHSHRGY	3036


Matching phase	Type of match	Number linked	%

1	Child’s first, middle, and last name & dob and mother’s dob	5282	2.6 %

2	Child’s first, middle initial, and last name & dob and mother’s dob	32094	16.0 %

3	Child’s first, middle, and last name & dob	3035	1.5 %

4	Child’s first, middle initial, and last name & dob	66730	33.3 %

5	Child’s first and last name & dob	90506	45.2 %

6	Child’s first 3 letters of first name and last name & dob	2696	1.3 %


Number	Authors, year	c	Age, sex	Period (years)	symptoms	Preoperative lab	Treatment	Histological diagnosis	Outcomes

1	Boriani et al, 1978 [8]	S1-3	18, M	DNMI	Bone pain, weakness	Hypophosphatemia, elevated ALP	Complete resection, radiotherapy	Osteosarcoma	NOLF

2	Stone et al, 1992 [9]	T3-4	33, F	DNMI	Bone pain, weakness, fractures	Hypophosphatemia	Complete resection, supplementation of vitamin D, phosphate, and calcium	Neuroendocrine tumor	NOLF

3	Yu et al, 1995 [10]	C2	58, F	DNMI	Musculoskeletal pain, weakness	Hypophosphatemia, elevated ALP and PTH	Partial resection, supplementation of vitamin D and phosphate	PMT	PSA

4	Terek et al, 2001 [11]	S1-2	14, M	1+	Bone pain, skeletal abnormalities	Hypophosphatemia, hypocalcemia, low level of vitamin D3, elevated ALP	Partial resection, chemotherapy (doxorubicin)	Osteosarcoma	PSA, ALL

5	Dissanayake et al, 2003 [37]	L2	58, M	3+	Musculoskeletal pains, fractures	Hypophosphatemia, low level of vit D3, elevated ALP	Complete resection	Haemangiopericytoma	NOLF

6	Folpe et al, 2004 [5]	C1	32, F	4	DNMI	DNMI	Partial resection, radiotherapy	Malignant PMTMCT	PSA recurrence

7	Chua et al, 2008 [12]	T3	34, F	1	Musculoskeletal pain, fatigue	Hypophosphatemia, hypocalcemia, elevated ALP and PTH	Partial resection, supplementation of phosphate and calcitriol	Plasmacytoma	DNMI

8	Sciubba et al, 2009 [13]	T8	56, F	5	Bone pain, weakness, fractures	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH	Complete resection	PMT	NOLF

9	Pirola et al, 2009 [14]	T4	57, M	DNMI	Fractures, paresthesias	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH	Complete resection, supplementation of vitamin D and phosphate	PMT	NOLF

10	Mavrogenis et al, 2010 [15]	S1	42, F	2	Bone pain, paresthesias	Normal	Complete resection	PMTMCT	NOLF

11	Marshall et al, 2010 [16]	T12	55, F	6+	Bone pain; fractures	Hypophosphatemia	Complete resection	PMTMCT	DNMI

12	Akhter et al, 2011 [17]	C5	52, M	1	Fracture	Hypophosphatemia	Complete resection, supplementation of vitamin D, and phosphate	PMTMCT	NOLF

13	Gandhi et al, 2012 [18]	L4	66, F	2,	Bone pain, weakness	Hypophosphatemia, hypocalcemia, low level of vit D3, elevated ALP and PTH	Complete resection	PMTMCT	NOLF

14	Nakamura et al, 2014 [19]	C5	72, M	2.5	Weakness	Hypophosphatemia, elevated ALP and PTH	Complete resection, supplementation of phosphate and calcitriol.	PMTMCT	NOLF

15	Puthenveetil et al [38]	T12	61, F	7	Musculoskeletal pain, weakness, fractures	Hypophosphatemia, increased ALP	Complete resection, supplementation of calcium and phosphate	PMTMCT	NOLF

16	Present case	T1	60, M	6	Bone pain, weakness, paresthesia	Hypophosphatemia, hypocalcemia, elevated PTH	Complete resection, supplementation of calcitriol	PMT	NOLF

Number	Authors, year	c	Age, sex	Period (years)	symptoms	Preoperative lab

1	Boriani et al, 1978 [8]	S1-3	18, M	DNMI	Bone pain, weakness	Hypophosphatemia, elevated ALP

2	Stone et al, 1992 [9]	T3-4	33, F	DNMI	Bone pain, weakness, fractures	Hypophosphatemia

3	Yu et al, 1995 [10]	C2	58, F	DNMI	Musculoskeletal pain, weakness	Hypophosphatemia, elevated ALP and PTH

4	Terek et al, 2001 [11]	S1-2	14, M	1+	Bone pain, skeletal abnormalities	Hypophosphatemia, hypocalcemia, low level of vitamin D3, elevated ALP

5	Dissanayake et al, 2003 [37]	L2	58, M	3+	Musculoskeletal pains, fractures	Hypophosphatemia, low level of vit D3, elevated ALP

6	Folpe et al, 2004 [5]	C1	32, F	4	DNMI	DNMI

7	Chua et al, 2008 [12]	T3	34, F	1	Musculoskeletal pain, fatigue	Hypophosphatemia, hypocalcemia, elevated ALP and PTH

8	Sciubba et al, 2009 [13]	T8	56, F	5	Bone pain, weakness, fractures	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH

9	Pirola et al, 2009 [14]	T4	57, M	DNMI	Fractures, paresthesias	Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH

10	Mavrogenis et al, 2010 [15]	S1	42, F	2	Bone pain, paresthesias	Normal

11	Marshall et al, 2010 [16]	T12	55, F	6+	Bone pain; fractures	Hypophosphatemia

12	Akhter et al, 2011 [17]	C5	52, M	1	Fracture	Hypophosphatemia

13	Gandhi et al, 2012 [18]	L4	66, F	2,	Bone pain, weakness	Hypophosphatemia, hypocalcemia, low level of vit D3, elevated ALP and PTH

14	Nakamura et al, 2014 [19]	C5	72, M	2.5	Weakness	Hypophosphatemia, elevated ALP and PTH

15	Puthenveetil et al [38]	T12	61, F	7	Musculoskeletal pain, weakness, fractures	Hypophosphatemia, increased ALP

16	Present case	T1	60, M	6	Bone pain, weakness, paresthesia	Hypophosphatemia, hypocalcemia, elevated PTH

Treatment	Histological diagnosis	Outcomes

Complete resection, radiotherapy	Osteosarcoma	NOLF

Complete resection, supplementation of vitamin D, phosphate, and calcium	Neuroendocrine tumor	NOLF

Partial resection, supplementation of vitamin D and phosphate	PMT	PSA

Partial resection, chemotherapy (doxorubicin)	Osteosarcoma	PSA, ALL

Complete resection	Haemangiopericytoma	NOLF

Partial resection, radiotherapy	Malignant PMTMCT	PSA recurrence

Partial resection, supplementation of phosphate and calcitriol	Plasmacytoma	DNMI

Complete resection	PMT	NOLF

Complete resection, supplementation of vitamin D and phosphate	PMT	NOLF

Complete resection	PMTMCT	NOLF

Complete resection	PMTMCT	DNMI

Complete resection, supplementation of vitamin D, and phosphate	PMTMCT	NOLF

Complete resection	PMTMCT	NOLF

Complete resection, supplementation of phosphate and calcitriol.	PMTMCT	NOLF

Complete resection, supplementation of calcium and phosphate	PMTMCT	NOLF

Complete resection, supplementation of calcitriol	PMT	NOLF


	Year

	1992 (n = 321)	2000 (n = 433)	2008 (n = 607)	Trend

	%	n	%	n	%	n	χ2 (d.f. = 1)	P

No diagnosis specified	39	124	24	102	31	189

 Bad news	76	94	73	74	48	91	26.653	< 0.001

 Understanding mental illness	6	8	14	14	24	45	17.096	< 0.001

 Services and advocacy	18	22	14	14	28	53	5.692	0.017

Depression	28	91	34	149	37	226

 Bad news	38	35	32	47	28	63	3.287	0.070

 Understanding mental illness	46	42	59	88	63	142	6.643	0.010

 Services and advocacy	15	14	9	14	9	21	1.976	0.160

Eating disorders	14	45	13	58	14	82

 Bad news	58	26	16	9	17	14	20.297	< 0.001

 Understanding mental illness	42	19	78	45	78	64	14.682	< 0.001

 Services and advocacy	0	0	7	4	5	4	-	-

Anxiety disorders	10	32	14	62	11	67

 Bad news	19	6	21	13	18	12	0.38	0.845

 Understanding mental illness	63	20	69	43	72	48	0.760	0.383

 Services and advocacy	19	6	10	6	10	7	-	-

Schizophrenia	12	38	14	59	9	57

 Bad news	58	22	49	29	68	39	1.535	0.215

 Understanding mental illness	16	6	27	16	25	14	0.758	0.384

 Services and advocacy	26	10	24	14	7	4	6.443	0.011

Bipolar disorder	4	12	3	11	3	19

 Bad news	50	6	64	7	21	4	-	-

 Understanding mental illness	33	4	9	1	53	10	-	-

 Services and advocacy	17	2	27	3	26	5	-	-

Personality disorders	2	7	6	26	1	9

 Bad news	86	6	85	22	56	5	-	-

 Understanding mental illness	0	0	8	2	33	3	-	-

 Services and advocacy	14	1	8	2	11	1	-	-

ADHD	0	0	4	18	4	24

 Bad news	0	0	22	4	8	2	-	-

 Understanding mental illness	0	0	72	13	88	21	-	-

 Services and advocacy	0	0	6	1	4	1	-	-

Other disorders	1	2	1	5	1	7

 Bad news	50	1	40	2	14	1	-	-

 Understanding mental illness	0	0	60	3	71	5	-	-

 Services and advocacy	50	1	0	0	14	1	-	-

	Year

Bad news	76	94	73	74	48	91	26.653	< 0.001

Understanding mental illness	6	8	14	14	24	45	17.096	< 0.001

Services and advocacy	18	22	14	14	28	53	5.692	0.017

Depression	28	91	34	149	37	226

Bad news	38	35	32	47	28	63	3.287	0.070

Understanding mental illness	46	42	59	88	63	142	6.643	0.010

Services and advocacy	15	14	9	14	9	21	1.976	0.160

Eating disorders	14	45	13	58	14	82

Bad news	58	26	16	9	17	14	20.297	< 0.001

Understanding mental illness	42	19	78	45	78	64	14.682	< 0.001

Services and advocacy	0	0	7	4	5	4	-	-

Anxiety disorders	10	32	14	62	11	67

Bad news	19	6	21	13	18	12	0.38	0.845

Understanding mental illness	63	20	69	43	72	48	0.760	0.383

Services and advocacy	19	6	10	6	10	7	-	-

Schizophrenia	12	38	14	59	9	57

Bad news	58	22	49	29	68	39	1.535	0.215

Understanding mental illness	16	6	27	16	25	14	0.758	0.384

Services and advocacy	26	10	24	14	7	4	6.443	0.011

Bipolar disorder	4	12	3	11	3	19

Bad news	50	6	64	7	21	4	-	-

Understanding mental illness	33	4	9	1	53	10	-	-

Services and advocacy	17	2	27	3	26	5	-	-

Personality disorders	2	7	6	26	1	9

Bad news	86	6	85	22	56	5	-	-

Understanding mental illness	0	0	8	2	33	3	-	-

Services and advocacy	14	1	8	2	11	1	-	-

ADHD	0	0	4	18	4	24

Bad news	0	0	22	4	8	2	-	-

Understanding mental illness	0	0	72	13	88	21	-	-

Services and advocacy	0	0	6	1	4	1	-	-

Other disorders	1	2	1	5	1	7

Bad news	50	1	40	2	14	1	-	-

Understanding mental illness	0	0	60	3	71	5	-	-

Services and advocacy	50	1	0	0	14	1	-	-


Trait (nm)	Standard diet	Standard diet + ATRA


Method of risk assessment	Definition	Advantages	Limitations

Clinical prediction rules	The use of a scoring system based on patient- or procedure-related risk factors to quantify risk	Often cost-neutral	Estimates population risk for patient rather than providing an individualized risk assessment

 	 	Requires no specialist knowledge[34]

ASA-PS	Six-point scale used to grade patient according to comorbidities[35]	Validated in a number of settings[36-38]	Inter-observer variability[39]

 	 	 	Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40]

Lee Revised Cardiac Risk Index (RCRI)	Scores patients according to six variables, including whether the surgery is high risk	Discriminates moderately well between patients at low versus high risk for cardiac events after mixed noncardiac surgery[42]	Designed to identify patients at risk of cardiac complications so may miss patients at risk of other complications who may benefit from PACU care

 	Assesses cardiac risk[41]	Well validated

POSSUM	A more detailed scoring system with 18 components, 6 operative variables and 12 physiological variables[46]	A revision of POSSUM, the Portsmouth POSSUM[43] has been shown to be a better predictor of outcome in certain surgical settings[33,44,45]	Some variables cannot be ascertained until after surgery, making it of limited use for preoperative identification of patients who may benefit from PACU care

 	 	Variations in the model have been devised for specific patient groups, such as the Cr-POSSUM (colorectal), which has been shown to be a better predictor of outcome in this type of surgery[47]

Cardiopulmonary exercise testing	CPET is an integrative and quantitative measure of a patient’s cardiopulmonary reserve	Good evidence that CPET is useful to help predict perioperative morbidity and mortality and may aid triage to an appropriate level of postoperative care[48-50]	In 2008, 17% of Hospital Trusts in England had a CPET service, and a further 7% were in the process of setting one up[52]

The assessment requires the patient to exercise (usually on a cycle ergometer) while oxygen consumption, carbon dioxide production, and other cardiorespiratory variables are measured	RCT in progress to further evaluate its use to stratify to appropriate level of postoperative care[51]

Method of risk assessment	Definition	Advantages	Limitations

			Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40]

Lee Revised Cardiac Risk Index (RCRI)	Scores patients according to six variables, including whether the surgery is high risk	Discriminates moderately well between patients at low versus high risk for cardiac events after mixed noncardiac surgery[42]	Designed to identify patients at risk of cardiac complications so may miss patients at risk of other complications who may benefit from PACU care

	Assesses cardiac risk[41]	Well validated

POSSUM	A more detailed scoring system with 18 components, 6 operative variables and 12 physiological variables[46]	A revision of POSSUM, the Portsmouth POSSUM[43] has been shown to be a better predictor of outcome in certain surgical settings[33,44,45]	Some variables cannot be ascertained until after surgery, making it of limited use for preoperative identification of patients who may benefit from PACU care

		Variations in the model have been devised for specific patient groups, such as the Cr-POSSUM (colorectal), which has been shown to be a better predictor of outcome in this type of surgery[47]

Cardiopulmonary exercise testing	CPET is an integrative and quantitative measure of a patient’s cardiopulmonary reserve	Good evidence that CPET is useful to help predict perioperative morbidity and mortality and may aid triage to an appropriate level of postoperative care[48-50]	In 2008, 17% of Hospital Trusts in England had a CPET service, and a further 7% were in the process of setting one up[52]

The assessment requires the patient to exercise (usually on a cycle ergometer) while oxygen consumption, carbon dioxide production, and other cardiorespiratory variables are measured	RCT in progress to further evaluate its use to stratify to appropriate level of postoperative care[51]


Polymorphism	Reference allele homozygote	Heterozygote	Variant allele homozygote

PAI-2 (SERPINB, rs6095)

Event Rate (%)	34.7	14.6	6.7

Number of patients	72	48	15

Number of patients (%)	53.3	35.6	11.1

LRP-1 (LRP1, rs1800156)

Event Rate (%)	21.1	24.5	33.3

Number of patients	57	53	18

Number of patients (%)	44.5	41.4	14.1

p22phox (CYBA, rs4673)*

Event Rate (%)	36.9	15.1	8.0

Number of patients	65	53	25

Number of patients (%)	45.5	37.1	17.5

TSP-4 (THBS4, rs1866389)*

Event Rate (%)	17.9	36.6	50.0

Number of patients	95	41	4

Number of patients (%)	67.9	29.3	2.9

CETP (CETP, rs708272)*

Event Rate (%)	14.9	26.4	33.3

Number of patients	47	72	24

Number of patients (%)	32.9	50.4	16.8


Group	Location	Gender	Age range (years)	Number of participants

One	ROI	Female	20-29	8

Two	ROI	Female	30-40	9

Three	ROI	Male	29-39	8

Four	NI	Male	29-59	6

Five*	NI	Male	20-25	7

Six	NI	Female	21-59	4

Seven	NI	Male	19-24	8

Eight†	NI	Female	39-45	4

Nine	NI	Female	22-63	5

Ten‡	NI	Female	35-64	7

Group	Location	Gender	Age range (years)	Number of participants

Two	ROI	Female	30-40	9

Three	ROI	Male	29-39	8

Four	NI	Male	29-59	6

Five*	NI	Male	20-25	7

Six	NI	Female	21-59	4

Seven	NI	Male	19-24	8

Eight†	NI	Female	39-45	4

Nine	NI	Female	22-63	5

Ten‡	NI	Female	35-64	7


Gene/Gene Cluster Name	Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)	Protein	Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.)	Predicted Antimicrobial Resistance Profile	Tested Antibiotics	Profile

gcvA-blaOCH	contig00009 (QGST01000009.1)coordinates: 164,062–165,431	class Cbeta-lactamase	[98%] Ochrobactrum tritici C8846-N36 (SME85995)	penams, penems,cephalosporins, cephamycins, monobactams	AMPCFMCTXCRO	RRRR

transcriptional regulator GcvA	[98%] Ochrobactrum anthropi (WP_061347328)

acrAB-TolC	contig00001 (QGST01000001.1)coordinates: 191,438-196,605	transcriptional regulator TetR	[93%] Ochrobactrum oryzae (WP_104756164)	tetracyclines, cephalosporins penams, phenicols, ryfamycins, fluoroquinolones	AMPCIPCFMCTXCROTEMXFRIF	RSRRRSSR

efflux RND transporter periplasmic adaptor subunit	[98%] Ochrobactrum anthropi (WP_061344971)

efflux RND transporter permease subunit	[99%] Ochrobactrum anthropi (WP_061344972)

acrAB-TolC	contig00010 (QGST01000010.1)coordinates: 49,666–54,163	efflux RND transporter periplasmic adaptor unit	[98%] Ochrobactrum sp. (WP_024900215)

efflux RND transporter permease subunit	[99%] Ochrobactrum oryzae (WP_104755654)

qacH	contig00007 (QGST01000007.1)coordinates: 192,104–191,772	efflux SMR transporter	[100%] Ochrobactrum sp. (WP_010661279)	fluoroquinolones	CIPMXF	SS

cmlA/floR	contig00016 (QGST01000016.1)coordinates: 56,907–55,714	CmlA/floR chloramphenicol efflux MFS transporter	[94%] Ochrobactrum anthropi(WP_061345584)	chloramphenicol	C	R

acc (6’)	contig00016 (QGST01000016.1)coordinates: 92,931–92,485	aminoglycoside 6’-acetyl-transferase	[93%] Ochrobactrum anthropi FRAF13(KXO77791)	aminoglycosides	CN	S

tetG-tetR	contig00014 (QGST01000014.1)coordinates: 7148–9063	Tet(A/B/C) family MFS transporter	[87%] Ochrobactrum oryzae(WP_104755825)	tetracyclines	TE	S

transcriptional regulator tetR	[89%] Ochrobactrum oryzae(WP_104755986)


	Fixed effects model	Growth curve model 1	Growth curve model 2

Fixed part

 Intercept	0.820 (0.756 to 0.884)	0.823 (0.779 to 0.866)	0.830 (0.791 to 0.87)

 Age-centred (linear term)	−0.008 (−0.01 to –0.007)	−0.007 (−0.008 to –0.006)	−0.006 (−0.007 to –0.004)

 Age (quadratic term)	−0.0003 (−0.0004 to –0.0003)	−0.0002 (−0.0002 to –0.0001)	−0.0002 (−0.0002 to –0.0002)

 p, 2df	<0.001	<0.001	<0.001

 Frequency of public transport use(ref: every day or nearly every day)

 Two or three times a week	−0.012 (−0.024 to 0.0001)	−0.006 (−0.016 to 0.003)	−0.005 (−0.018 to 0.008)

 Once a week	−0.020 (−0.034 to –0.005)	−0.011 (−0.022 to –0.0002)	−0.006 (−0.019 to 0.008)

 No use: no need	−0.018 (−0.032 to –0.003)	−0.011 (−0.022 to –0.001)	−0.005 (−0.018 to 0.008)

 No use: health problems	−0.058 (−0.075 to –0.040)	−0.090 (−0.104 to –0.077)	−0.115 (−0.135 to –0.095)

 No use: structural reasons	−0.020 (−0.035 to –0.006)	−0.009 (−0.019 to 0.002)	−0.002 (−0.014 to 0.011)

 p, 5df		<0.001	<0.001

 Interaction between age (linear term) and frequency of public transport use

 Age* two or three times a week			−0.0003 (−0.002 to 0.001)

 Age* once a week			−0.001 (−0.002 to 0.0004)

 Age* no use: no need			−0.001 (−0.002 to –0.00002)

 Age* no use: health problems			0.002 (0.0001 to 0.003)

 Age* no use: structural reasons			−0.001 (−0.003 to –0.0002)

 p, 5df			<0.001

Random part

 Level 2 (individual)

 Intercept variance		0.0238	0.0238

 Age-centred (linear term) variance	0.00002	0.00002

 Covariance of intercept and age centred	−0.0004	−0.0004

 Level 1 (wave)

 Intercept		0.020	0.020

 N observations (level 1)	27 509	27 509	27 509

 N clusters (level 2)	9656	9656	9656

 Goodness of fit	Adj R-sq: 0.7273	Deviance: −13 719.59	Deviance: −13 746.54

	Fixed effects model	Growth curve model 1	Growth curve model 2

Level 1 (wave)

Intercept		0.020	0.020

N observations (level 1)	27 509	27 509	27 509

N clusters (level 2)	9656	9656	9656

Goodness of fit	Adj R-sq: 0.7273	Deviance: −13 719.59	Deviance: −13 746.54


Characteristic

Age

< = 50

51-60

61-70

> 70

Tumor (T)

T1

T2

T3

T4

Lymph nodes (N)

N0

N1

Metastasis (M)

M0

M1

Grade (G)

G1

G2

G3


	Month 1	Month 16	Month 21	Total samplen = 72

Decisions to be made, n (%)

Medical admission or treatment	17 (81)a	12 (44)a	8 (33)a	37 (51)

Psychiatric admission or treatment	5 (24)	13 (48)	13 (54)	31 (43)

Agreement status, n (%)

Agreeing	5 (24)	15 (56)	12 (50)	32 (44)

Not agreeing(or unable to express a choice/not documented)	16 (76)	12 (44)	12 (50)	40 (56)

	Month 1	Month 16	Month 21	Total samplen = 72

Agreement status, n (%)

Agreeing	5 (24)	15 (56)	12 (50)	32 (44)

Not agreeing(or unable to express a choice/not documented)	16 (76)	12 (44)	12 (50)	40 (56)


Food composition of major foods in Uganda (per 100 g of edible portion)

Food	Calories	Protein (g)	Iron (Mg)

Finger millet	346	8.7	4.0

Sorghum	354	10.2	4.1

Ground nuts	577	27.1	2.5

Cowpeas	330	22.4	5.0

Bananas	100	1.5	0.4

Cassava	350	1.8	2.0

Maize	354	9.0	2.5

Beans	330	19.5	8.0

Simsim	593	20.1	9.8

Sweet Potato	166	1.3	1.2

Per capita of protein and calories derived from the major foods

Food	Protein	Calories

	Teso	Uganda	Teso	Uganda

Finger millet	53.40	8.46	2292	497

Sorghum	22.0	5.13	704	164

Ground nuts	27.20	6.03	571	126

Cowpeas	38.00	3.51	570	53

Bananas	0.30	3.24	26	324

Cassava	3.70	3.96	814	854

Maize	7.10	7.21	258	261

Beans	3.90	12.25	55	172

Simsim	3.30	1.53	99	46

Sweet Potato	4.80	2.70	365	205

Others	0	1.83	708	123

Total	163.70	55.85	6462	2825


Cluster #	Expression level

High	Medium high	Medium	Medium low	Low

1	Ribosome	Lumen	Lumen	Lumen	DNA repair/Stress response

2	Oxidative Phosphorylation	Cytoskeleton	Chromosome structure	Zinc finger PHD	Zinc/ion binding

3	Ubiquitination	Protein catabolism	Protein complexes	Transcriptional regulation	Protein catabolism

4	Spliceosome	Chromosome structure	Mitochondrial subunits	Mitochondrial matrix	Protein transport

5	RNA binding	Nucleic acid binding	Nucleic acid binding/Phospho-rylation	Ankyrin repeats	tRNA aminoacylation

6	Electron transport	Ubiquitination	Endoplasmic reticulum	Protein/nucleotide interactions	Zinc finger CH2

7	Protein localization	Protein complex synthesis	Cell cycle	Microtubules	Cell death

8	Protein biosynthesis	Cell cycle	Cellular membranes	Mitochondrial membranes	DNA repair/Polymerase

9	Ribosomal subunits	Mitochondrial components	Ankyrin repeats	Phosphorylation	Suppression of differentiation

10	Protein folding	RNA splicing	tRNA	Zinc finger CH2	Nucleic acid binding

Cluster #	Expression level

High	Medium high	Medium	Medium low	Low

1	Ribosome	Lumen	Lumen	Lumen	DNA repair/Stress response

2	Oxidative Phosphorylation	Cytoskeleton	Chromosome structure	Zinc finger PHD	Zinc/ion binding

3	Ubiquitination	Protein catabolism	Protein complexes	Transcriptional regulation	Protein catabolism

4	Spliceosome	Chromosome structure	Mitochondrial subunits	Mitochondrial matrix	Protein transport

5	RNA binding	Nucleic acid binding	Nucleic acid binding/Phospho-rylation	Ankyrin repeats	tRNA aminoacylation

6	Electron transport	Ubiquitination	Endoplasmic reticulum	Protein/nucleotide interactions	Zinc finger CH2

7	Protein localization	Protein complex synthesis	Cell cycle	Microtubules	Cell death

8	Protein biosynthesis	Cell cycle	Cellular membranes	Mitochondrial membranes	DNA repair/Polymerase

9	Ribosom	Mitochondrial 		Phosphorylat	Suppression

	al subunits	components	Ankyrin repeats	ion	 of differentiation

10	Protein folding	RNA splicing	tRNA	Zinc finger CH2	Nucleic acid binding


Primary reference, Study, Country (secondary references)	Objectives	Design	Sample size	Patient population	Follow-up

Treatment-related observational studies

Driessen 2008[68], Radboud University Registry, The Netherlands (Driessen 2009[69])	Efficacy and tolerability of etenercept and efalizumab	Registry	118	Psoriasis	24 weeks

Fortune 2003[6], PUVA Study, UK and Ireland	Role of psychological distress on PUVA treatment outcomes	Cohort	112	Plaque psoriasis (chronic)	2 years

Lecha 2005[70], Spanish tacalcitol ointment study	Efficacy and tolerability of tacalcitol	Cohort	556	Psoriasis (moderate)	2 months

Naldi 2008[71], Psocare, Italy	Effect of BMI on clinical response to systemic treatment	Cohort	2368	Plaque psoriasis	3 years

Paul 2003[72] Cyclosporine study, Europe and Canada	Incidence of malignancies in cyclosporine treated patients	Cohort	1252	psoriasis - severe	5 years

Wahl 2005[73], Climate therapy study, Norway	Effectiveness of climate therapy	Cohort	286	Psoriasis	8 months

Heiberg 2008[74], Norwegian register of disease modifying anti-rheumatic drugs, (Heiberg 2007[75])	Comparative effectiveness of TNF inhibitors vs. methotrexate monotherapy	Registry	526	Psoriatic arthritis	1 year

Kristensen 2008[76], South Swedish Arthritis Treatment Group register, (Gulfe 2009[77], Geborek 2002[78], Kristensen 2006[79])	Efficacy, utility and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)	Registry	261	Psoriatic arthritis	7 years

Sparado 1997[80], Cyclosporin Study, Italy	Probability of continuing to take cyclosporine vs. other DMARDS	Cohort	172	Psoriatic arthritis	10 years

Saad 2009[81], British Society for Rheumatology Biologics Register, (Harrison 2009[82], Silman 2003[83])	Effectiveness and tolerability of TNF-inhibitors (etanercept, infliximab, adalimumab)	Registry	566	RA, psoriasis, psoriatic arthritis	1 year

Non-treatment related observational studies

Carrascosa 2006[84], EPIDERMA cost of illness, Spain	Direct and indirect cost; relationship between cost and severity	Cohort	797	Psoriasis	1 year

Colombo 2008[11], Cost of illness, Italy	Direct and indirect cost; HRQOL; relationship between cost, HRQOL and severity	Cohort	150	Moderate to severe plaque psoriasis	3 months

Schmid-ott 2005[85], Bad Bentheim Rehabilitation Hospital, Germany	Relationship between the degree of stigmatisation and gender, skin symptoms, PASI and SPASI	Cohort	166	Psoriasis	1 year

Ali 2007[86], Husted 2007[2], Gladman 2009[16], Rohekar 2008[87], Toronto PsA clinic, Canada, (Chandran 2007[88], Gladman 1995[89], Gladman 1998[90], Gladman 1999 [91], Gladman 2001[92], Husted 2005[93], Wong 1997[94])	(1) Mortality associated with PsA; (2) relationship between physical functioning, disease activity and joint damage; (3) CVD associated with PsA; (4) malignancies associated with PsA	Cohort	382 to 680	Psoriatic arthritis	26 years

Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])	Clinical presentation, outcome and prognosis of early PsA	Cohort	129	Early psoriatic arthritis	2 years

Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98])	Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients	Registry	135	Early psoriatic arthritis	2 years

Primary reference, Study, Country (secondary references)	Objectives	Design	Sample size	Patient population	Follow-up

Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])	Clinical presentation, outcome and prognosis of early PsA	Cohort	129	Early psoriatic arthritis	2 years

Lindqvist 2008[97], SwePsA registry, Sweden, (Svensson 2002[98])	Factors associated with disease progression; outcome of treated and non-treated groups, comparison of outcomes with RA patients	Registry	135	Early psoriatic arthritis	2 years


Characteristics	No OSA	Mild-Moderate OSA	Severe OSA	p value

n = 10	n = 33	n = 34

Total sleep time (minutes)	288.2 ± 88.2	268.3 ± 80.7	253.8 ± 74.6	0.207


Animal group	Body weight (g)	Blood glucose (mg/dL)


Symbol	Name	Function	Reference

PLK1	polo-like kinase 1	cell cycle regulation	[13-19]

CDK16	cyclin-dependent kinase 16	cell cycle regulation	[20]

RYK	receptor-like tyrosine kinase	cellular growth and differentiation Regulation	[21]

MTOR	mechanistic target of rapamycin (serine/threonine kinase)	cellular metabolism, growth, and proliferation Regulation	[22-24]

STK17B	serine/threonine kinase 17b	positive regulation of apoptosis	[25]

PLK4	polo-like kinase 4	cell cycle regulation	[17,26]

MAST2	microtubule associated serine/threonine kinase 2	cellular growth and differentiation Regulation	[27]

MAP3K4	mitogen-activated protein kinase kinase kinase 4	role in signal transduction cascades	[28]

MARK2	MAP/microtubule affinity-regulating kinase 2	cell polarity and microtubule dynamics regulation	[29]

CDK1	cyclin-dependent kinase 1	cell cycle regulation	[13,15-17,30,31]

NEK2	NIMA (never in mitosis gene a)-related kinase 2	cell cycle regulation	[14-16,30]

PRKCSH	protein kinase C substrate 80K-H	roles in inflammation, cell growth, signaling and death	[32]

AURKA	aurora kinase A	cell cycle regulation	[33,34]

BUB1	mitotic checkpoint serine/threonine kinase	cell cycle regulation	[35]

CDC7	cell division cycle 7 homolog (S. cerevisiae)	cell cycle regulation	[30]

SRPK1	SRSF protein kinase 1	cellular growth and differentiation Regulation	[36]

TTK	TTK protein kinase	cell cycle regulation	[14-16,37,38]

VRK1	vaccinia related kinase 1	cell cycle regulation	[39,40]

Symbol	Name	Function	Reference

AURKA	aurora kinase A	cell cycle regulation	[33,34]

BUB1	mitotic checkpoint serine/threonine kinase	cell cycle regulation	[35]

CDC7	cell division cycle 7 homolog (S. cerevisiae)	cell cycle regulation	[30]

SRPK1	SRSF protein kinase 1	cellular growth and differentiation Regulation	[36]

TTK	TTK protein kinase	cell cycle regulation	[14-16,37,38]

VRK1	vaccinia related kinase 1	cell cycle regulation	[39,40]


		Dietary supplementationa	Statistical significance of variance ratio (P)b, effects of

	Control	TTA	FO	TTA + FO	TTA	FO	TTA*FO

CPT-I	2.79 ± 0.26c	1.69 ± 0.38	2.54 ± 0.12	1.75 ± 0.14	<0.001	0.22	0.06


 	D-dimer ≥10 μg/mL after treatment

 	No	Yes	p∗

 	(n = 31)	(n = 21)

Male sex	18 (58.1%)	10 (47.6%)	0.458

Age, years	63 (55–71)	63 (55–70)	0.970

DWI patterns	 	 	0.724

 Single vascular territory	6 (19.4%)	3 (14.3%)

Single lesion	3	2

Multiple lesions	3	1

 Multiple vascular territories	25 (80.6%)	18 (85.7%)

Treatment	 	 	0.002

 Enoxaparin	21 (67.7%)	5 (23.8%)

 Warfarin	10 (32.3%)	16 (72.6%)

Cancer profiles

 Primary cancer type	 	 	0.586

Lung	15 (48.4%)	12 (57.1%)

Gastrointestinal	4 (12.9%)	3 (14.3%)

Hepatobiliary	5 (16.1%)	5 (23.8%)

Breast-gynecologic	4 (12.9%)	1 (4.8%)

Other	3 (9.7%)	0 (0%)

 Systemic metastasis	23 (74.2%)	20 (95.2%)	0.067

 Adenocarcinoma	19 (61.3%)	17 (85.0%)	0.070


Generic name	Study drug name (Brand name)	Active ingredient content	Manufacturers/distributors

amlodipine besilate	Amlodin® tablets 2.5	containing 2.5 mg of amlodipine	Sumitomo Pharmaceuticals Co., Ltd.

	Amlodin® tablets 5	containing 5 mg of amlodipine

	Norvasc® tablets 2.5 mg	containing 2.5 mg of amlodipine	Pfizer Japan Inc.

	Norvasc® tablets 5 mg	containing 5 mg of amlodipine


BPG	Patient Eligibility Criteria 	Participating Program Units

Asthma	Patients who present to the participating units with a primary or secondary diagnosis of asthma	Emergency, in-patient and medical units

Breastfeeding	Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delivered by a midwife. Additional infant criteria included: no major congenital anomalies, no galactasemia. Additional postpartum women criteria included: no documented use of street drugs, no major psychiatric illness, baby not up for adoption.	Labour and delivery, postpartum, neonatal intensive care, and public health unit

Delirium-Dementia-Depression	Clients admitted to participating units, age 65 years and older.	Surgical, medical and rehabilitation units

Smoking Cessation	Clients age 18 years and older admitted to participating unit. For outpatients, admission to out-patient services within the past month and currently attending the clinic.	In-patient and out-patient long-term mental health, in-patient unit for drug and alcohol addition, in-patient unit for acute psychiatric disorders, resource unit for nicotine dependency

Venous Leg Ulcers	All clients with new and recurrent venous leg ulcers. Patients with primary lymphedema, vasculitis, and under diabetic management excluded.	Chronic care unit, wound care clinic, and community care agency

Diabetes	Adults age 18 and over with a diagnosis of diabetes admitted to one of the participating units. Women with gestational diabetes excluded.	Oncology, medical and diabetes care and education centre and community care agency

BPG	Patient Eligibility Criteria	Participating Program Units

Breastfeeding	Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delivered by a midwife. Additional infant criteria included: no major congenital anomalies, no galactasemia. Additional postpartum women criteria included: no documented use of street drugs, no major psychiatric illness, baby not up for adoption.	Labour and delivery, postpartum, neonatal intensive care, and public health unit

Delirium-Dementia-Depression	Clients admitted to participating units, age 65 years and older.	Surgical, medical and rehabilitation units

Smoking Cessation	Clients age 18 years and older admitted to participating unit. For outpatients, admission to out-patient services within the past month and currently attending the clinic.	In-patient and out-patient long-term mental health, in-patient unit for drug and alcohol addition, in-patient unit for acute psychiatric disorders, resource unit for nicotine dependency

Venous Leg Ulcers	All clients with new and recurrent venous leg ulcers. Patients with primary lymphedema, vasculitis, and under diabetic management excluded.	Chronic care unit, wound care clinic, and community care agency

Diabetes	Adults age 18 and over with a diagnosis of diabetes admitted to one of the participating units. Women with gestational diabetes excluded.	Oncology, medical and diabetes care and education centre and community care agency


Organism	Precision	Recall	F-score

Mouse	0.77	0.81	0.79

Yeast	0.97	0.84	0.90

Fly	0.83	0.80	0.82

FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries	0.74	0.83	0.79

Human	0.86	0.81	0.84


Command	Value	Description

ACK	0×06	It is sent when a frame has been received and decoded correctly.

NACK	0×15	It is sent when a frame has not been decoded correctly.

RESET	0×08	It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central computer to reprogram the device.

ALIFE	0×0C	This command is sent to a specific node to check if it is in working mode. If the board is correctly working, it answers with an ACK command.


	N	%	% susceptible TMP/SMX	Ciprofloxacin	Nitrofurantoin

E. coli	73	82	93	100	95

P. mirabillis	5	5.6	100	100	na

K. pneumonia	4	4.4	100	100	50

S. aureus	3	3.3	100	0	100

C. koseri	2	2.2	100	100	100

B-hemolytic Strep	1	1.1	na	na	na

S. saphophyticus	1	1.1	0	100	100

Total	89	100


Dimension	Categories

Primary diagnosis	Organic mental health problem (most commonly dementia)

Depression or anxiety

Other mental health problem e.g., schizophrenia

Main reason for admission	Risk of deliberate self-harm

Other risks i.e., self-neglect, accidental self-harm, abuse/exploitation or falls, or carer stress

Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown

Need for diagnostic assessment, medication review or treatment

Challenging behaviour	Low (behaviour score 0 or 1)

Medium (behaviour score 2–7, typically including agitation, wandering and/or disturbed sleep)

High (behaviour score 8–14, typically including resistance to care and/or aggression)

Living situation	Resident primary carer (including care home residents)

No resident carer

Main reason for admission	Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown

Need for diagnostic assessment, medication review or treatment

Challenging behaviour	Low (behaviour score 0 or 1)

Medium (behaviour score 2–7, typically including agitation, wandering and/or disturbed sleep)

High (behaviour score 8–14, typically including resistance to care and/or aggression)

Living situation	Resident primary carer (including care home residents)

No resident carer


Adsorbent	qm (mg/g)	Ref.

GO sponge	446	[38]

GO-CS sponge	468	[39]

GO-Fe3O4 sponge	526	[40]

RGO sponge	27	[38]

RGO-MFe2O4	34.72	[41]

RL-GO	529.10	[42]

MCGO	95.16	[43]

GO-biopolymer gel	701.78	[44]

GO-COOH sponge	780 ± 47	This study


Characteristic, N (%)	Arm AN = 22	Arm BN = 14	Arm CN = 14	P value

Age at randomization

18–39 years	2 (9)	5 (36)	1 (7)

40–49 years	8 (36)	0	5 (36)

50–59 years	5 (23)	4 (29)	7 (50)

≥ 60 years	7 (32)	5 (36)	1 (7)	0.02

Extent of surgery

Breast sparing	9 (41)	6 (43)	6 (43)

Mastectomy	13 (59)	8 (57)	8 (57)	0.99

Tumor size


Dataset	Note	Reference

Global	289 isolates; Human and environmental isolates, from six countries (Australia, Indonesia, Laos, Singapore, Vietnam, USA), sampled to maximize diversity and exclude members of a clonal outbreak, metadata includes invasiveness, acquisition type and sample site. Invasiveness status of human isolates consists of three types: carriage (isolates not considered to be the cause of an infection), non-invasive (pneumonia, urinary tract infection, wound infection; with no recorded bacteraemia) and invasive (isolated from normally sterile sites: blood, CSF, intra-ocular, pleural, pericardial, joint fluids, deep-seated tissue abscesses). Acquisition type is either community acquisition (isolated within 48 hours of admission to hospital) or hospital acquisition (isolated after 48 hours after admission)	(Holt et al. 2015)

UK Hospital	162 isolates; Collection from Cambridge University Hospitals NHS Foundation Trust in the UK over a period of seven years, invasive isolates isolated from normally sterile sites. Biased selection for antimicrobial resistance to three or more of six antimicrobial classes (penicillins, amoxacillin-clavulanate, aminoglycosides, fluoroquinolones, trimethoprim and third-generation cephalosporins), metadata includes sample site	(Ellington 2016)

Nepal Hospital	88 isolates; Nepalese hospital outbreak from May to December 2012, consisting mainly of two clonal lineages; randomly selected blood cultures.	(Chung The et al. 2015)

Preantibiotic	34 isolates; Collection of isolates isolated before the widespread use of antibiotics (pre 1949). No additional metadata available.	(Wand et al. 2015)


Mother’s educational genetic score, standardized		−0.14 (0.11)

Father’s highest grade completed	0.13† (0.04)	0.13† (0.04)	0.17† (0.01)	0.17† (0.01)

Father’s educational genetic score, standardized		0.00 (0.09)

Constant	8.45 (0.74)†	8.65† (0.90)	−26.95 (26.80)	−35.35 (26.54)

R2	0.16	0.17	0.18	0.20


Cell growth inhibition ratios (%)

Cell groups	time

	24 h	48 h	72 h

HepG2	55.45 ± 1.4	68.91 ± 1.8	78.83 ± 3.9

	1.00 ± 	1	1.72 ± 0


Standard sections	Keywords

Introduction	Introduction, Background, Review, Context, Literature

Materials and Methods	Methods, Materials, Implementation, Experimental

Results	Results, Findings

Discussion	Discussion

Conclusion	Conclusion(s)

Standard sections	Keywords

Introduction	Introduction, Background, Review, Context, Literature

Materials and Methods	Methods, Materials, Implementation, Experimental

Results	Results, Findings

Discu	Discussion


	Patients

Characteristic	No.	%

Median age at onset (yr)	4 (0.1-15.7)

Gender

 Female	74	81

 Male	17	19

JIA onset subtype

 Oligoarticular	62	68

 Polyarticular	29	32

NSAID*

 Naproxen	87	95

 Meloxicam	4	4

 Tolmetin	11	12

 Ibuprofen	16	18

 Rofecoxib	6	7

 Diclofenac	8	9

 Celecoxib	3	3

 Nabumetone	2	2

Other Medications†	6	7

Median duration of treatment (yr)

 Oligoarticular	1.5 (0.14-17.7)

 Polyarticular	0.58 (0.11-9.8)

	Patients

Characteristic	No.	%

Diclofenac	8	9

Celecoxib	3	3

Nabumetone	2	2

Other Medications†	6	7

Median duration of treatment (yr)

Oligoarticular	1.5 (0.14-17.7)

Polyarticular	0.58 (0.11-9.8)


No	Pathotype	AGE	N 9-p	N 10-p	N 14-p	Micro	Sexta

 1	EAggEC	P

 2	EAggEC	P			L	L

 3	EAggEC	P				L

 4	EAggEC	P	L	L	L	L	L

 5	EAggEC	P			L		L

 6	EAggEC		L	L	L	L

 7	EAggEC	P		L	L	L	L

 8	EAggEC	P			L	L

 9	EAggEC	P		L	L	L

10	EAggEC	P		L	L	L	L

11	EIEC		L	L	L	L	L

12	EIEC		L	L	L	L	L

13	EIEC		L	L	L	L	L

14	EPEC

15	EPEC			L	L

16	EPEC

17	EPEC

18	EPEC		L	L	L

19	EPEC	P		L	L	L	L

20	EPEC	P

21	EPEC	P

22	EPEC	P	L	L	L

23	EPEC	P				L

24	EPEC					L	L

25	EPEC			L	L

26	EPEC				L		L

27	EPEC	P

28	EPEC	P		L	L		L

29	VTEC		L	L	L	L	L

30	VTEC		L	L	L	L	L

31	VTEC		L	L	L	L

32	ETEC O114	P		L	L	L

33	ETEC O167	P				L	L

34	ETEC O6	P			L

35	ETEC O25	P		L	L

36	ETEC O25	P

37	ETEC O78	P		L	L	L	L

38	ETEC O115	P		L	L

39	ETEC O114	P

40	ETEC O115	P				L	L

41	ETEC O25	P				L

42	ETEC O115	P

43	ETEC O6	P	L	L	L

44	ETEC O167	P

45	ETEC O114	P		L	L	L

46	ETEC O8	P

No	Pathotype	AGE	N 9-p	N 10-p	N 14-p	Micro	Sexta

38	ETEC O115	P		L	L

39	ETEC O114	P

40	ETEC O115	P				L	L

41	ETEC O25	P				L

42	ETEC O115	P

43	ETEC O6	P	L	L	L

44	ETEC O167	P

45	ETEC O114	P		L	L	L

46	ETEC O8	P


Proximates

Moisture (g/100 g)

Ash (g/100 g)

Protein (g/100 g)

Fat (g/100 g)

Fiber (g/100 g)

Carbohydrate (g/100 g)

Energy (Kcal/100 g)

Amino acids(mg/g)

Asp

Thr

Ser

Glu

Gly

Ala

Cys

Val

Met

Ile

Leu

Tyr

Phe

Lys

His

Arg

Pro

Total amino acids(mg/g)

Minerals

Calcium (g/100 g)

Phosphorus (g/100 g)


Factor	Level	n	Test +ve	%	OR	95 % CI	χ2	P value

Farm type	Extensive	33	14	42.4

Intensive	4	3	75	4.07	0.38–43.38	1.52	0.22

Level	n	Test +ve	%	OR	95 % CI	χ2	P value

Extensive	33	14	42.4

Intensive	4	3	75	4.07	0.38–43.38	1.52	0.22


Line	Patients by gender identity	Number (a)

20	Male

21	Female

22	Transgender male/female-to-male

23	Transgender female/male-to-female

24	Other

25	Choose not to disclose

26	Total patients (sum lines 20 to 25)


IQ	TMT interference	Stroop interference	ZOO MAP


Age (years)

Gender (M-men/W-women)

BMI (kg/m2)

RBC (×1012 cells/l)

Hb (g/dl)

Platelets count (×109 cells/l)

WBC count (×109 cells/l)

CRP (mg/l)

CA19.9 (U/ml)

Subjective pain intensity (n [%])

None

Delicate

Moderate

Intensive

General feeling (n [%])

Good

Poor

Terrible/very weak


Patients	n = 13

Mean age years (min – max)	53 (28–77)

Male/female	7/6

Mean height cm (min-max)	166 (146–177)

Mean weight kg (min-max)	72 (44–105)

Mean BMI (min-max)	27 (19–38)

ASA I/II/III/IV	2/4/2/5

Mallampati class I/II/III/IV	6/2/2/3

Orally/nasally awake fiberoptic intubation	6/7

Reasons for awake fiberoptic intubation

 o Cervical spine disease, i.e. rheumatoid arthritis	5

 o Head and neck abnormality, i.e. supraglottic cancer, oral abscess	2

 o Thyroidea abnormality	3

 o Upper airway trauma, i.e. acute pharyngeal bleeding, mandible fracture	3

Previous experience with anaesthesia, yes/no	10/3

Patients

Mean age years (min – max)

Male/female

Mean height cm (min-max)

Mean weight kg (min-max)

Mean BMI (min-max)

ASA I/II/III/IV

Mallampati class I/II/III/IV

Orally/nasally awake fiberoptic intubation

Reasons for awake fiberoptic intubation

o Cervical spine disease, i.e. rheumatoid arthritis

o Head and neck abnormality, i.e. supraglottic cancer, oral abscess

o Thyroidea abnormality

o Upper airway trauma, i.e. acute pharyngeal bleeding, mandible fracture

Previous experience with anaesthesia, yes/no


Genome	Proteome size	Clustered proteins	Core proteome

Halobacterium sp. NRC-1	2626	2174 (82.8%)	857 (32.6%)

Haloarcula marismortui 	4240	3464 (81.7%)	893 (23.1%)

Natronomonas pharaonis 	2822	2285 (81.0%)	847 (30.0%)

Haloquadratum walsbyi 	2626	2108 (80.3%)	835 (31.8%)

Halorubrum lacusprofundi 	3913	3166 (80.9%)	870 (22.2%)

Halogeometricum borinquense 	4303	3209 (74.6%)	891 (20.7%)

Halomicrobium mukohataei 	3548	2902 (81.8%)	858 (24.2%)

Halorhabdus utahensis 	3160	2334 (73.9%)	856 (27.1%)

Haloferax volcanii 	4074	3240 (79.5%)	870 (21.4%)

Genome	Proteome size	Clustered proteins	Core proteome

Halobacterium sp. NRC-1	2626	2174 (82.8%)	857 (32.6%)

Haloarcula marismortui	4240	3464 (81.7%)	893 (23.1%)

Natronomonas pharaonis	2822	2285 (81.0%)	847 (30.0%)

Haloquadratum walsbyi	2626	2108 (80.3%)	835 (31.8%)

Halorubrum lacusprofundi	3913	3166 (80.9%)	870 (22.2%)

Hal	4	3209 (74.6	891


Strains	Characteristics	Source/origin

J940047	Wild-type isolate	Clinical, Portugal

J940557	Wild-type isolate	Clinical, Portugal

J940915	Wild-type isolate	Clinical, Portugal

06L3FF02	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L1FF11	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L3FF15	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

06L6FF20	Wild-type isolate	Wine cellar; Bairrada Wine Region, Portugal

UM218	Wild-type isolate	Vineyard; Vinho Verde Wine Region, Portugal

UM237	Wild-type isolate	Vineyard; Vinho Verde Wine Region, Portugal

BB1235	Wild-type isolate	Vineyard; Bairrada Wine Region, Portugal

BB2453	Wild-type isolate	Vineyard; Bairrada Wine Region, Portugal

Lalvin EC-1118	Commercial; used in the Vinho Verde Wine Region	Champagne, France

Lalvin ICV D254	Commercial; used in the Bairrada Wine Region	Rhône Valley, France

IOC 18–2007	Commercial; used in the Bairrada Wine Region	Institut Oenologique de Champagne, France

AEB Fermol Rouge	Commercial; used in the Bairrada Wine Region	Montpellier University, France

Davis Lalvin 522	Commercial; used in the Bairrada Wine Region	University of California, Davis, USA

S288C	MATα SUC2 mal mel gal2 CUP1 flo1 flo8-1	Mortimer & Johnston, 1986 [87]

Strains	Characteristics	Source/origin

BB2453	Wild-type isolate	Vineyard; Bairrada Wine Region, Portugal

Lalvin EC-1118	Commercial; used in the Vinho Verde Wine Region	Champagne, France

Lalvin ICV D254	Commercial; used in the Bairrada Wine Region	Rhône Valley, France

IOC 18–2007	Commercial; used in the Bairrada Wine Region	Institut Oenologique de Champagne, France

AEB Fermol Rouge	Commercial; used in the Bairrada Wine Region	Montpellier University, France

Davis Lalvin 522	Commercial; used in the Bairrada Wine Region	University of California, Davis, USA

S288C	MATα SUC2 mal mel gal2 CUP1 flo1 flo8-1	Mortimer & Johnston, 1986 [87]


Gene	Accession number	Forward Primer (5'-3')	Reverse Primer (5'-3')	qPCR primer combination (product length)	Sequencing primer combination (product length)

GST mu 1	AF462190	F1: GCTATTGGGATCTTCGTGGA	R1:TGCCCAAATACCGGAGAATA	F1/R1 (228 bp)	F1/R2 (628 bp)

			R2: TGTATTCCATTTCGCCATTG

GST mu 2	AY825933	F1: GCCCATCAGAATGATGCTTT	R1: TTCTCAAGATAATCTGGCTTTA	F1/R1 (344 bp)	F1/R2 (519 bp)

			R2: GAATCGATTAACATAGTTGCC

GST mu 3	AY825934	F1: ATCTGGCGTGCAGATAAAC	R1: CTCGAGCCTTCTCGAAATTG	F1/R1 (241 bp)	F2/R2 (929 bp)

		F2: ACGCAGTTTTGTTTCGTTGG	R2: GTCTGGATTTGTTCCGTGGT

GST delta 1	AY825935	F1: TGGACCAACATTAGCCGATA	R1: TTGCATTTGTTGAGCGAATC	F1/R1 (193 bp)	F2/R1 (631 bp)

		F2: CAGAAAGTGCACCATGTCGT

GST delta 2	AY825936	F1: AGCTCAAACCGATGAGCCTA	R1:GCGAATGCAATGATGTTAGC	F1/R1 (192 bp)	F2/R1 (652 bp)

		F2:TGGGTTCTATTCGACCGATAA

GST delta 3	AY825937	F1: ATGGAGGTGGTTTGAACGAG	R1: TCGTGATCGACAGCATTCAT	F1/R1 (244 bp)	F2/R1 (580 bp)

		F2: AGAGAGCCCACCATGTCGTA

P-glycoprotein	DQ146410	AGGCAACTTCAGCACTCGAT	ACATTCTGACCGCCATCAAT	155 bp

SsCl	EF611372	TGATTTCTATATGTCGGGCCATTTG	CAGGGAACCAAAGATCAACA	329 bp

β-actin	EU624346	CAACCATCCTTCTTGGGTATG	CCAGCTTCGTCGTATTCTTGT	311 bp


Characteristics	HR	95% CI	P-value

Health knowledgea

 Low (0)	1

 Moderate (1–3)	0.63	0.33–1.19	0.15

 High (4–15)	0.43	0.22–0.86	0.02

Age	1.04	1.00–1.07	0.04

Sex	0.81	0.42–1.58	0.54

Smoking status

 Never	1

 Current	2.24	1.13–4.44	0.02

 Former	0.92	0.25–3.34	0.90

Comorbidities

 Hypertension

No	1

Yes	0.96	0.50–1.85	0.91

 Hyperlipidemia

No	1

Yes	1.88	1.00–3.55	0.05

 Atrial fibrillation

No	1

Yes	3.61	1.28–10.20	0.02

 Coronary artery disease

No	1

Yes	1.16	0.67–2.01	0.60

 Congestive heart failure

No	1

Yes	1.61	0.75–3.45	0.22


	Different scales	Mean	SD	Score ≥ 3,5 (total)

Images of God (5 point scale)	Personal God	2,75	1,42	18 (50)

Non-personal God	2,70	0,75	24 (49)

Unknowable God	3,23	1,18	19 (46)

Attitudes towards death (5 point scale)	Explicitly religious	2,53	1,34

Agnostic/Atheistic	3,35	0,96

Reincarnation	2,17	1,08

Community	2,43	1,24

Continuation	2,70	1,27

Spiritual wellbeing scales (4 point scale)	Existential wellbeing	2,96	,59

Relation to Self	3,05	,54

Relation to Others	3,30	,50

Relation to Something Greater	2,40	,73

Relation to God (1-item scale for ‘believers’ n = 29 completed this scale)	2,38	1,02


	Frequencies of graft cell subsets, (%), mean ± SD		Doses of graft cell subsets infused, 106 cells/kg of body weight, median (min–max)

G-BM (	G-PBSC (n = 52		G	G-PBSC


Characteristics	No. (%)

Sex

M	65 (67%)

F	32 (33%)

Age (years)


Pt.	Indication for tons.	CP type	Initial cleft repair	Protons. endoscopy	Posttons. endoscopy	Speech intelligibility	VPI Severity

Preop.	postop.	Diff.	Preop.	Postop.	Diff.

4	VPI	SM	Unk.	Palate 9 lat 4	Palate 9 lat 4	2	2	0	2	2	0

5	VPI	None	None	Palate 7 lat 2	Palate 9 lat 4	2	2	0	3	2	−1

6	VPI	UC	2 flap	Palate 0 lat 0	Palate 0 lat 1	3	2	−1	2	2	0

7	VPI	UC	2 flap	Palate 9 lat 2	Palate 9 lat 1	3	2	−1	1	2	1

9	VPI	UC	2 flap	Palate 1 lat 1	Palate 2 lat 1	3	4	1	4	4	0

12	VPI	UC	2 flap	Palate 5 lat 1	Palate 5 lat 3	4	4	0	4	4	0

15	Recurrent strep + VPI	I	2 flap	Palate 8 lat 4	Palate 9 lat 4	2	1	−1	1	2	1

16	VPI	None	None	Palate 9 lat 4	Palate 7/8, lat 1	3	3	0	3	3	0

17	OSA	UC	2 flap	Palate 8 lat 0	Palate 8 lat 1	2	2	0	2	2	0

22	VPI	SM	furlow	Palate 4 lat 0	Palate 3.5 lat 1	4	4	0	3	3	0

Pt.	Indication for tons.	CP type	Initial cleft repair	Protons. endoscopy	Posttons. endoscopy	Speech intelligibility	VPI Severity

Preop.	postop.	Diff.	Preop.	Postop.	Diff.

12	VPI	UC	2 flap	Palate 5 lat 1	Palate 5 lat 3	4	4	0	4	4	0

15	Recurrent strep + VPI	I	2 flap	Palate 8 lat 4	Palate 9 lat 4	2	1	−1	1	2	1

16	VPI	None	None	Palate 9 lat 4	Palate 7/8, lat 1	3	3	0	3	3	0

17	OSA	UC	2 flap	Palate 8 lat 0	Palate 8 lat 1	2	2	0	2	2	0

22	VPI	SM	furlow	Palate 4 lat 0	Palate 3.5 lat 1	4	4	0	3	3	0


Genes	Primer Sequences (5'-3')	Cycles	Size (bp)	Annealing Temperature (°C)

Pluripotency-associated markers

Oct4	F	TCTCGCCCCCTCCAGGT	30	218	53

	R	GCCCCACTCCAACCTGG

Sox2	F	GGCAGCTACAGCATGATGCAGGACC	34	130	60

	R	CTGGTCATGGAGTTGTACTGCAGG

Endodermal-associated markers

FoxA2	F	GGGAGCGGTGAAGATGGA	38	89	55

	R	TCATGTTGCTCACGGAGGAGTA

Gata6	F	GAGTGAGAGAAGATGGAAGGG	38	250	55

	R	CGCACATGAAATCTGGATGTGG

Ectodermal-associated markers

Nestin	F	CAGCTGGCGCACCTCAAGATG	30	209	55

	R	AGGGAAGTTGGGCTCAGGACTGG

Pax6	F	AACAGACACAGCCCTCACAAACA	30	275	55

	R	CGGGAACTTGAACTGGAACTGAC

Mesodermal-associated markers

Brachyury	F	GAACCAGCACCCTGTGTCCAC	38	608	57

	R	GCCACGACAAAAAGTCACTGC

Goosecoid	F	CTCAACCAGCTGCACTGTC	38	322	55

	R	GTCAGCTGTCCGAGTCCAAATC

Control-associated markers

GAPDH	F	ATGGAGAAGGCTGGGGCTC	28	196	55

	R	AAGTTGTCATGGATGACCTTG

Genes

Pluripotency-associated markers

Oct4

Sox2

Endodermal-associated markers

FoxA2

Gata6

Ectodermal-associated markers

Nestin

Pax6

Mesodermal-associated markers

Brachyury

Goosecoid

Control-associated markers

GAPDH

Primer Sequences (5'-3')	Cycles	Size (bp)	Annealing Temperature (°C)

Pluripotency-associated markers

F	TCTCGCCCCCTCCAGGT	30	218	53

R	GCCCCACTCCAACCTGG

F	GGCAGCTACAGCATGATGCAGGACC	34	130	60

R	CTGGTCATGGAGTTGTACTGCAGG

Endodermal-associated markers

F	GGGAGCGGTGAAGATGGA	38	89	55

R	TCATGTTGCTCACGGAGGAGTA

F	GAGTGAGAGAAGATGGAAGGG	38	250	55

R	CGCACATGAAATCTGGATGTGG

Ectodermal-associated markers

F	CAGCTGGCGCACCTCAAGATG	30	209	55

R	AGGGAAGTTGGGCTCAGGACTGG

F	AACAGACACAGCCCTCACAAACA	30	275	55

R	CGGGAACTTGAACTGGAACTGAC

Mesodermal-associated markers

F	GAACCAGCACCCTGTGTCCAC	38	608	57

R	GCCACGACAAAAAGTCACTGC

F	CTCAACCAGCTGCACTGTC	38	322	55

R	GTCAGCTGTCCGAGTCCAAATC

Control-associated markers

F	ATGGAGAAGGCTGGGGCTC	28	196	55

R	AAGTTGTCATGGATGACCTTG


Referrals & Services	Team 1	Team 2	Team 3	Team 4	Team 5

	T1	A2	T	A	T	A	T	A	T	A

# of referrals	1104	61	0	0	172	10	2742	152	250	14

# of new registration	418	23	1163	65	81	5	488	27	71	4

# of consultation	1889	105	7207	400	107	6	2682	149	110	6

# of telephone contact with Patient	328	18	2296	128	76	4	585	33	50	3

# of telephone contact with family members	0	-	0	-	33	2	43	2	15	1

Referrals & Services	Team 1	Team 2	Team 3	Team 4	Team 5

	T1	A2	T	A	T	A	T	A	T	A

# of consultation	1889	105	7207	400	107	6	2682	149	110	6

# of telephone contact with Patient	328	18	2296	128	76	4	585	33	50	3

# of telephone contact with family members	0	-	0	-	33	2	43	2	15	1


WAT	Continuous grazing	Rotational grazing	Rotational grazing + parasiticide fungi

	G-1 (n = 6)a	G-2 (n = 8)b	G-3 (n = 8)c


 Screening options

Fecal screening tests	These tests search for occult blood in stool, which is nonspecific but can be detected especially in larger polyps and CRC. It is important to collect samples from consecutive bowel movements [39, 40].Guaiac fecal occult blood test (gFOBT) detects qualitatively heme in the stool, using a guaiac material to which hydroperoxidase is added. Heme promotes a process that leads to the guaiac's oxygenation and to a blue discoloration [41, 42]. It has a low sensitivity for the detection of CRC, but when performed every year or two, mortality is reduced [39, 43, 44].Fecal immunochemical tests (FITs) use monoclonal or polyclonal antibodies to detect human haemoglobin. They can give qualitative or quantitative results. FIT is more accurate than gFOBT, because it does not react with nonhuman heme and is less sensitive to upper gastrointestinal tract's bleeding [41, 45].

Endoscopic screening	Flexible Sigmoidoscopy is a screening option that allows examining the rectum and the lower part of the colon. It is an invasive technique that requires simple bowel preparation but cannot detect lesion in the whole colon [41, 45].Colonoscopy is esteemed as the gold standard for CRC screening; it allows exploring the whole colon and removing the suspicious lesions [46, 47]. It is an invasive and expensive exam that must be performed if any other test has a positive result [39]. The most common side effect is postpolypectomy bleeding, but also tearing and perforation may be possible [45]. It is recommended that colonoscopy be practiced every 10 years in average-risk patients that underwent to a complete, negative exam [39, 48, 49].

CT-colonography (CTC)	CTC is a noninvasive test that has become a common method for CRC screening. It requires a bowel preparation, but sedation is not needed. The estimated sensitivity and sensibility in detecting polyps > 1 cm are high, above 90%. Limitation of this technique includes low sensitivity for small lesion and serrated polyps, the exposure to radiation, and the need of follow-up for extra colic incidental findings [39, 49–51].


Effect:	Relevancea	Pointsb	Classc

 	 	1	2	3	4	5

1	Temperature: Heat-related mortality	6	2	1	 	 	41	IV

2	Temperature: Heat-related cardiovascular problems	1	 	2	 	 	11	III

3	Temperature: Heat-related respiratory problems	1	1	 	1	 	11	III

4	Temperature: Heat-related stress and sleep disturbance	1	 	 	 	 	5	II

5	Temperature: Cold-related mortality	 	 	 	 	 	 	I

6	Temperature: Cold-related diseases	 	 	 	 	 	 	I

7	Temperature: Drought-related exposure to contaminants	 	 	 	 	 	 	I

8	Temperature: Shortages of drinking water	 	 	 	 	1	1	II

9	Temperature: Dehydration	 	2	 	 	 	8	II

10	Allergies: Asthma	 	 	1	 	1	4	II

11	Allergies: Allergic eczema	 	 	 	 	 	 	I

12	Allergies: Hay fever: duration of pollen season	 	2	 	1	2	12	III

13	Allergies: Hay fever: pollen types, abundance and allergenicity	 	2	1	 	 	11	III

14	Pests: Wasps	 	 	 	 	 	 	I

15	Pests: Oak processionary caterpillar	 	1	 	 	 	4	II

16	Vector-borne: Native vector-borne diseases	1	1	 	 	1	10	II

17	Vector-borne: Incidents of non-native vector-borne diseases	1	2	2	1	 	21	IV

18	Vector-borne: Epidemics of non-native vector-borne diseases	2	 	 	2	 	14	III

19	Food/water-borne: Food poisoning	 	 	 	1	 	2	II

20	Food/water-borne: Legionnaires Disease	 	 	 	 	1	1	II

21	Food/water-borne: Contamination of swimming/recreation water	 	 	 	1	2	4	II

22	Air quality: Respiratory problems due to ground-level ozone	 	 	1	2	 	7	II

23	Air quality: Respiratory problems due to particulate matter	 	 	 	 	 	 	I

24	Air quality: Air quality-related cardiovascular problems	 	 	 	1	1	3	II

25	Flood/storm: Flood-related mortality	1	 	1	1	 	10	II

26	Flood/storm: Flood-related infectious diseases	 	 	 	 	 	 	I

27	Flood/storm: Flood-related exposure to dangerous substances and contaminants	 	 	1	 	 	3	II

28	Flood/storm: Flood-related respiratory problems	 	 	 	 	 	 	I

29	Flood/storm: Flood-related mental health problems	 	1	 	 	2	6	II

30	Flood/storm: Storm-related mortality and injury	 	 	 	 	 	 	I

31	UV: Cataract	 	 	 	 	 	 	I

32	UV: Skin cancer	 	 	2	 	 	6	II

33	UV: Weakening of the immune system	 	 	 	 	 	 	I

34	OTHER: societal disruption elsewhere	1	 	 	 	 	5	II


Catchment Area	Size of catchment area population	Public Corporation	Third Sector	Private Company	Different MTC

BSIC	Different MTC	BSIC	Different MTC	BSIC	Different MTC

Länsi-Uusimaa (1)	35296	13	11	6	4	4	2	16

Lohja (2)	70379	17	8	14	7	9	3	16

Hyvinkää (3)	139734	41	13	37	15	16	2	26

Porvoo (4)	74611	17	8	20	7	6	2	13


Parameters	Supplemented group (n = 9)	Control group (n = 7)

Age (years)	21.3 ± 0.82	21.3 ± 0.71

Body mass (kg)	93.6 ± 6.02	81.6 ± 9.44

Body height (cm)	192.6 ± 6.53	189.0 ± 4.62

Duration of training (years)	7.5 ± 1.5	6.9 ± 1.2


Species	Age (M)	DiseaseStage*	Gene	Expression, HD/Control	SEM	t-value	p-value

Mouse	3		Casp2	.704	.063	1.78	> 0.05

Mouse	6		Casp2	1.15	.11	0.56	> 0.05

Mouse	9		Casp2	1.20	.12	0.71	> 0.05

Species	Age (M)	DiseaseStage*	Gene	Expression, HD/Control	SEM	t-value	p-value

Mouse	12		Casp2	1.01	.12	0.08	> 0.05

Human**		0-2	Casp2	0.996		-0.14	> 0.05

Human**		0-2	HMGCR	0.739		-5.04	< 0.001


Strain	Phenotypeb	Vancomycin MIC (μg/ml) by Etest after various periods of incubation

CLSI classification (48 h)	New classification	Without antibiotics	With mupirocin at 0.032 μg/ml

48 h	72 h	96 h	120 h	144 h	48 h	72 h	96 h	120 h	144 h

209P	VSSA (MSSA)	VSSA (MSSA)	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

N315ΔIP	VSSA (MRSA)	VSSA (MRSA)	2	2	2	2	2	2	2	2	2	2

Mu3	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

Mu50	VISA	VISA	12	12	12	12	12	12	12	12	12	12

MI (HIP5827)	VISA	VISA	12	12	12	12	12	12	12	12	12	12

Mu3-6R	VISA	Slow VISA	8	8	12	12	16	16	16	16	16	16

Clinical blood culture isolates from 9 hospitals

MRSA212	VSSA	VSSA	1.5	2	2	2	2	3	3	3	3	3

MRSA84	VSSA	hVISA	2	2	3	3	3	3	3	3	3	3

MRSA220	VSSA	hVISA	1.5	3	3	3	3	3	3	3	3	3

MRSA192	VSSA	hVISA	2	2	2	2	2	2	2	2	2	2

MRSA190	VISA	Slow VISA	4	8	8	8	8	12	12	12	12	12

MRSA194	VISA	Slow VISA	4	6	8	12	12	8	12	12	12	12

T series clinical blood culture isolatesa

T12	VISA	Slow VISA	4	4	8	8	8	8	8	8	8	8

T15	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T61	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T89	VISA	Slow VISA	4	8	16	16	16	16	16	16	16	16

T122	VISA	Slow VISA	4	8	8	8	8	6	6	8	8	8

T123	VISA	Slow VISA	4	6	8	8	8	6	8	8	8	8

T12-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T15-L	hVISA	hVISA	3	3	3	3	4	4	4	4	4	4

T61-L	hVISA	hVISA	3	3	3	3	4	6	6	6	6	6

T89-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T122-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3

T123-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3

Strain	Phenotypeb	Vancomycin MIC (μg/ml) by Etest after various periods of incubation

CLSI classification (48 h)	New classification	Without antibiotics	With mupirocin at 0.032 μg/ml

48 h	72 h	96 h	120 h	144 h	48 h	72 h	96 h	120 h	144 h

Mu3-6R	VISA	Slow VISA	8	8	12	12	16	16	16	16	16	16

Clinical blood culture isolates from 9 hospitals

MRSA212	VSSA	VSSA	1.5	2	2	2	2	3	3	3	3	3

MRSA84	VSSA	hVISA	2	2	3	3	3	3	3	3	3	3

MRSA220	VSSA	hVISA	1.5	3	3	3	3	3	3	3	3	3

MRSA192	VSSA	hVISA	2	2	2	2	2	2	2	2	2	2

MRSA190	VISA	Slow VISA	4	8	8	8	8	12	12	12	12	12

MRSA194	VISA	Slow VISA	4	6	8	12	12	8	12	12	12	12

T series clinical blood culture isolatesa

T12	VISA	Slow VISA	4	4	8	8	8	8	8	8	8	8

T15	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T61	VISA	Slow VISA	4	6	8	8	8	8	8	8	8	8

T89	VISA	Slow VISA	4	8	16	16	16	16	16	16	16	16

T122	VISA	Slow VISA	4	8	8	8	8	6	6	8	8	8

T123	VISA	Slow VISA	4	6	8	8	8	6	8	8	8	8

T12-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T15-L	hVISA	hVISA	3	3	3	3	4	4	4	4	4	4

T61-L	hVISA	hVISA	3	3	3	3	4	6	6	6	6	6

T89-L	hVISA	hVISA	3	3	3	3	3	3	3	3	3	3

T122-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3

T123-L	VSSA	VSSA	2	2	2	2	2	3	3	3	3	3


	All subjects	Placebo	Donation

	Group	Time	Time	Time

	F value	p value	F value	p value	F value	p value	F value	p value

Pmax	0.43	0.5219	9.54	<0.0001	4.13	<0.0001	6.48	<0.0001


		Number of resting follicles (%)

Group	Total number of follicles	Total

Unfrozen	249	203 (81.5 %)

Vitrification	482	467*** (96.9 %)

Slow-freezing	374	365*** (97.6 %)


	Average annual costs	References

Health care costs (per episode/year)

 Myocardial infarction	$18627	Bergenheim et al., 2012 [12]

 Heart failure	$14118	Bergenheim et al., 2012 [12]

 Stroke	$7939	Bergenheim et al., 2012 [12]

 Hypoglycemia events requiring medical assistance	$199	Bergenheim et al., 2012 [12]

 Severe hypoglycemia event	$146	Bergenheim et al., 2012 [12]

 Weight gain	$289	Bergenheim et al., 2012 [12]

Drug cost (per patient/year)

 Metformin, generic drug	$24	NADAC (January 2015) [22]

 Dipeptidyl peptidase-4 inhibitor, brand	$3500 ($3401; $3599)	NADAC (January 2015) [22]

 Sulfonylurea (glipizide), generic	$16	NADAC (January 2015) [22]

 Insulin glargine, brand	$3646	NADAC (January 2015) [22]


Nutrients	Incomes (€) per Person per Month	Primary	Secondary	Undergraduate	Postgraduate

Mean	SE 5	Difference with >2700 € 2	Relative Difference (%) 3	p	Mean	SE 5	Difference with >2700 € 2	Relative Difference (%) 3	p	Mean	SE 5	Difference with >2700 € 2	Relative Difference (%) 3	p	Mean	SE 5	Difference with >2700 € 2	Relative Difference (%) 3	p

Magnesium	<1200	350.7	13.1	51.6	12.8%	0.0003	357.7	3.3	29.8	7.7%	<0.0001	382.6	4.6	10.8	2.8%	0.0038	388.0	5.8	16.7	4.1%	<0.0001


	N=55

Motor score

 Voluntary movement score [0–20]	6.33 (5.71)

 Stiffness [0–8]	2.20 (2.14)

 Chorea [0–16]	5.19 (4.51)

 Precise movement [0–8]	4.06 (2.46)

Behavioural score

 Depression anxiety [0–20]	9.12 (5.01)

 Temper [0–8]	2.81 (2.18)

 Psychotic disorder [0–12]	1.35 (2.16)

 Cognition [0–12]	3.52 (2.97)

Functional score

 Functional score [0–7]	3.06 (2.53)

	N=55

Chorea [0–16]	5.19 (4.51)

Precise movement [0–8]	4.06 (2.46)

Behavioural score

Depression anxiety [0–20]	9.12 (5.01)

Temper [0–8]	2.81 (2.18)

Psychotic disorder [0–12]	1.35 (2.16)

Cognition [0–12]	3.52 (2.97)

Functional score

Functional score [0–7]	3.06 (2.53)


Characteristic	N

Gender

 Male/female 	33/90

Age

 21 to 30 y	22

 31 to 40 y	36

 41 to 50 y	30

 >50 y	35

Years in practice

 <5 y	19

 5 to 10 y	21

 11 to 20 y	34

 >20 y	49

Average number of clients with nonsurgicalknee osteoarthritis treated per year

 1 to 20	43

 21 to 40	42

 >40	38


Diagnostic miR(s)	Disease Setting	Description	Reference(s)

miR-20a, miR-24, miR-25, miR-145, miR-152, miR-199-5p, miR-221, miR-222, miR-223, miR-320	Lung Cancer	10 microRNAs were found to have significantly different expression levels in NSCLC serum samples compared with the control serum samples.	[24]

miR-10b, miR-155, miR-195, miR34a	Breast Cancer	Increased expression of miR-10b, miR-155, and miR-195 and decreased miR-34a was associated with disease.	[25]

miR-221	Ovarian Cancer, Melanoma, Lymphoma	Increase expression in several different cancers compared to control serum samples.	[27,28,29]

miR-141, miR-16, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, and miR-885-5p.	Prostate	Levels of these microRNAs were found to be higher in the serum of patients compared to controls.	[21,26]


Rank	GAN	[3]	Rank	Gene description

			S2N	SVM-RFE

1	M27891	•	1	2	cystatin C (CST3)

2	M28130	•	25	3	interleukin 8 (IL8)

3	M84526	•	5	1	D component of complement (adipsin) (DF)

4	M19507		131	7	myeloperoxidase (MPO)

5	Y00787	•	23	4	interleukin-8 precursor

6	M11722		71	41	deoxynucleotidyltransferase, terminal (DNTT)

7	X95735	•	2	11	zyxin (ZYX)

8	D88422		3	8	cystatin A (CSTA)

9	M27783		15	5	elastase 2, neutrophil (ELA2)

10	M96326	•	75	10	azurocidin 1 (AZU1)


	SLD (n = 20)	HAD (n = 20)

Body weight (g)

initial	198 ± 4	200 ± 5

1 week	257 ± 6	247 ± 6

6 weeks	450 ± 10	438 ± 10

70 days	525 ± 12	498 ± 12

Food intake (g/kg b.w./day)

1st week	116 ± 4	122 ± 4

6th week	74 ± 1	73 ± 1

last week	64 ± 2	66 ± 1

	SLD (n = 20)

Body weight (g)

initial	198 ± 4

1 week	257 ± 6

6 weeks	450 ± 10

70 days	525 ± 12

Food intake (g/kg b.w./day)

1st week	116 ± 4

6th week	74 ± 1

last week	64 ± 2


	Expression

Protein

TGF-beta	Positive

	Negative

E-cadherin	Positive

	Negative

PGC	Positive

	Negative


Sex	Progesterone (ng/ml)

Female	2.74 ± 0.44

Male	2.24 ± 1.61


Group	Description of the group	Strength

TM1	The total number of skills is 2; number of skills of each employee and task is 2.	The quantum of effort needed in every task is to be equal; each employee has the same contribution of maximum dedication and salary.

TM2	The amount of skills is 10; number of employee skills is 5–7; number of skills required in the task is 3-4.	The functionalities in TM2 and TM3 have the same TPG; the tasks have the same efforts; each employee has maximum dedication and salary.

TM3	The amount of skills is 15; number of employee skills is 6-7; number of skills required in the task is 2-3.

TM4	The amount of skills is 10; number of employee skills is 2-3; number of skills required in the task is 4-5.	The functionalities in TM4 and TM5 have the same TPG; the tasks have the same effort and each employee has maximum dedication and salary.

TM5	The amount of skills is 5; number of employee skills is 3-4; number of skills required in the task is 2-3.

Group	Description of the group	Strength

TM1	The total number of skills is 2; number of skills of each employee and task is 2.	The quantum of effort needed in every task is to be equal; each employee has the same contribution of maximum dedication and salary.

TM2	The amount of skills is 10; number of employee skills is 5–7; number of skills required in the task is 3-4.	The functionalities in TM2 and TM3 have the same TPG; the tasks have the same efforts; each employee has maximum dedication and salary.

TM3	The amount of skills is 15; number of employee skills is 6-7; number of skills required in the task is 2-3.

T	The amount o	The functionalities in TM4 and TM5 have the same TPG; the tas

M4	f skills is 10; number of employee skills is 2-3; number of skills required in the task is 4-5.	ks have the same effort and each employee has maximum dedication and salary.

TM5	The amount of skills is 5; number of employee skills is 3-4; number of skills required in the task is 2-3.


Gender	Age (years)	Length of diagnosis of hypothyroidism (years)

Female	93	13

Female	80	10

Male	84	Approx. 8

Female	82	24

Male	83	15

Female	88	9

Female	85	14

Female	80	3

Female	83	14

Female	82	18

Female	85	16

Gender	Age (years)	Length of diagnosis of hypothyroidism (years)

Female	82	24

Male	83	15

Female	88	9

Female	85	14

Female	80	3

Female	83	14

Female	82	18

Female	85	16


Abbreviated Trial Name/NCT#	Phase	Agent(s)	Study population	Expected Primary Endpoint

NCT01935921	Ib	Cetuximab, ipilimumab and IMRT	stage III-IVaHPV+ OPSCC	Dose limiting toxicities (DLT)

RTOG 3504NCT02764593	III w/phase I lead in	Nivolumab and cisplatin CRT	stage III-IV, intermediate to high risk HNSCC	DLT for phase I

NCT02777385	II	Concurrent vs sequential pembro, cisplatin and IMRT	stage III-IVbHNSCC	1 year PFS1 year failure rateAcute toxicity rates

HN003NCT02775812	I	Adjuvant pembro, cisplatin and IMRT	high risk stage III-IV HSNCC	DLT

NCT02641093	II	Adjuvant pembro, cisplatin and IMRT	high risk stage III-IV HSNCC	Treatment related adverse events (TRAE)Disease free survival (DFS)


	Intervention	Control

All costs	USD	% total costs	USD	% total costs

Personnel	87 926	58.4	56 632	60.5

 CHWs (salaries and incentives)	10 332	6.9	3 982	4.3

 Field supervision and medical staff	28 193	18.7	17 194	18.4

 Management and technical staff	45 656	30.3	32 536	34.7

 Support staff (logistics, finance, administrative)	3 746	2.5	2 921	3.1

Programme costs	35 648	23.7	20 848	22.3

 Office and programme materials	1 756	1.2	1 324	1.4

 RUTF (supply)	17 795	11.8	5 648	6.0

 Training costs (trainer, location, supplies)	9 248	6.1	7 407	7.9

 Supervision and monitoring	6 849	4.6	6 469	6.9

Logistics	20 732	13.8	12 953	13.8

 Rent and utilities	8 927	5.9	2 767	3.0

 Transport (car rental, maintenance and fuel)	10 025	6.7	9 621	10.3

 RUTF transport and storage	1 780	1.2	565	0.6

Community contributions	6 218	4.1	3 208	3.4

 Costs to households	4 807	3.2	3 191	3.4

 Opportunity costs for community leaders	35	0.0	17	0.0

 Community-level rent	1 376	0.9	0	0.0

Total	150 523	100.0	93 641	100.0

Cost to government	11 881	7.9	5 341	5.7

Cost to partners	132 425	88.0	85 093	90.9

Cost to community	6 218	4.1	3 208	3.4


	Kegg pathway	Number of genes	Fold enrichment	p value*

UP	Steroid biosynthesis (cholesterol biosynthesis)	7	23.8	1.6E-07

Insulin signaling pathway	7	3.1	2.3E-02

Adipocytokine signaling pathway	5	5	1.6E-02

MAPK signaling pathway	9	2.5	2.4E-02

Glycolysis / Gluconeogenesis	4	4.5	5E-02

DOWN	Steroid biosynthesis (cholesterol biosynthesis)	4	27.8	3.3E-04

	Tight junction	6	5.3	4.6E-03

	Kegg pathway	Number of genes	Fold enrichment	p value*

U	Steroid biosynthesis (cholesterol biosynthesis)	7	23.8	1.6E-07

Ins		3	2.3

P	ulin signaling pathway	7	.1	E-02

Adipocytokine signaling pathway	5	5	1.6E-02

MAPK signaling pathway	9	2.5	2.4E-02

Glycolysis / Gluconeogenesis	4	4.5	5E-02

DOWN	Steroid biosynthesis (cholesterol biosynthesis)	4	27.8	3.3E-04

	Tight junction	6	5.3	4.6E-03


Details	HR-12 (current study)	93–11 [2]	IR-64 [3]	Kasalath [4]	Nipponbare [1]

Subspecies	indica	indica	indica	aus	japonica

Sequence depth	73x (Illumina) and 20x (PacBio)	4.2x (Sanger) and 36x (Illumina)	110x (Illumina)	6x (Roche 454) and 148X (Illumina)	6x (Sanger), 62x (Illumina) and 2.57x (Roche 454)

Sequencing technologies	Illumina and PacBio	Sanger and Illumina	Illumina	Illumina and Roche 454	Sanger, Illumina and Roche 454

Genome assembler(s)	MaSuRCA and PBJelly	RePS and SOAPDenovo	ALLPATHS-LG	Celera Assembler and String Graph Assembler	TIGR Assembler

Genome size (Mb)	389.77 (389.60)	374.55 (359.41)	345.9 (321.2)	401.14 (328.25)	374.47 (374.31)

No. of N's (Mb)	0.17	15.14	24.7	72.89	0.17

Total no. of contigs/scaffolds	59,692	50,231	26,160	51,550	NA

a. Anchored contigs/scaffolds	43,781	35,415	NA	36,932	NA

b. Unanchored contigs/scaffolds	15,911	14,816	NA	14,618	NA

N50 (Kb)	28.5	6.69	22.2	13.73	NA

No. of genes	56,284	40,464	37,758	53,662	55,986

CEG mapping (%)	94.35	95.97	94.35	95.97	95.97

Details	HR-12 (current study)	93–11 [2]

Subspecies	indica	indica

Sequence depth	73x (Illumina) and 20x (PacBio)	4.2x (Sanger) and 36x (Illumina)

Sequencing technologies	Illumina and PacBio	Sanger and Illumina

Genome assembler(s)	MaSuRCA and PBJelly	RePS and SOAPDenovo

Genome size (Mb)	389.77 (389.60)	374.55 (359.41)

No. of N's (Mb)	0.17	15.14

Total no. of contigs/scaffolds	59,692	50,231

a. Anchored contigs/scaffolds	43,781	35,415

b. Unanchored contigs/scaffolds	15,911	14,816

N50 (Kb)	28.5	6.69

No. of genes	56,284	40,464

CEG mapping (%)	94.35	95.97

IR-64 [3]	Kasalath [4]	Nipponbare [1]

indica	aus	japonica

110x (Illumina)	6x (Roche 454) and 148X (Illumina)	6x (Sanger), 62x (Illumina) and 2.57x (Roche 454)

Illumina	Illumina and Roche 454	Sanger, Illumina and Roche 454

ALLPATHS-LG	Celera Assembler and String Graph Assembler	TIGR Assembler

345.9 (321.2)	401.14 (328.25)	374.47 (374.31)

24.7	72.89	0.17

26,160	51,550	NA

NA	36,932	NA

NA	14,618	NA

22.2	13.73	NA

37,758	53,662	55,986

94.35	95.97	95.97


Location	Posture	Interpretation

None	None	No heat imprint found in frame. Due to the lack of heat imprint in frame, neither location nor posture can be identified.

Bed	Sitting Laying	The individual is either sitting up in bed or laying in bed. The heat imprint is within bed boundaries.

Bedrail	Sitting Laying	The individual is either sitting on the bed with legs partly outside bed, laying in the bed on the bedrail, or sitting on the floor with parts of the upper body, e.g., arms, in the bed. The latter is interpreted as laying on the bedrail. Laying on bedrail is considered hazardous.

Floor	Standing Sitting Laying	The person is either standing on the floor, sitting on the floor, or laying on the floor

Location	Posture	Interpretation

Floor	Standing Sitting Laying	The person is either standing on the floor, sitting on the floor, or laying on the floor


Groups	Day post-challenge

 	7	17	21	28

PCV2 in serum

Vaccinated group	3 of 5	3 of 5	2 of 5	0 of 5

Control group	5 of 5	5 of 5	5 of 5	5 of 5

Viral load in positive pigs

Vaccinated group	7.69 ± 0.11	7.67 ± 0.22	7.76 ± 0.26	0.00 ± 0.00

Control group	8.31 ± 0.40	8.41 ± 0.91	8.77 ± 0.55	7.72 ± 0.55


Manufacturer	Model	AEC System	Number of Times Tested

GE	Discovery 670a	AutomA 3D (AutomA & SmartmA)	2

GE	Discovery 670 Proa	1

GE	Discovery 690a	8

GE	Discovery 710a	1

GE	LightSpeed Ultra	5

GE	VCT	5

Philips	Gemini TFa	DoseRight 2.0	8

Siemens	Definition (Dual Source)		6 (12)

Siemens	Definition AS		8

Siemens	Definition AS+		3

Siemens	Definition AS+		1

Siemens	Definition Edge		1

Siemens	Emotion 16		2

Siemens	Sensation 16		7

Siemens	Sensation 16	CARE Dose 4D	5

Siemens	Sensation 64		6

Siemens	Sensation 64		7

Siemens	Sensation 64		6

Siemens	Sensation Openb		8

Siemens	Sensation Openb		6

Siemens	Sensation Openb		7

Siemens	Symbia Ta		2

Toshiba	Aquilion CXL	SURE Exposure 3D	4


Code	Communication items	Inpatient	Outpatient

 	 	Explaining	Breaking bad news	Discussing with a family	Explaining a diagnosis	Managing time	Managing a difficult consultation

1	Announcing the duration of the consultation	 	 	 	 	x

2	Establishing initial rapport	x	x	x	x	x	x

3	Setting the medical agenda	x	x	x	x	x	x

4	Introducing each other	 	 	x

5	Negotiating the agenda	 	 	x	x	x	x

6	Announcing	 	x

7	Exploring patient’s perspectives	x	x	x	x	x	x

8	Exploring patient’s understanding of what has happened	 	 	 	 	 	x

9	Summarizing the context	x	x	x	x	x	x

10	Informing	x	x	x	x	x	x

11	Clarifying roles, rules	 	 	x

12	Using clear language/no jargon	x	x	x	x	 	x

13	Chunking and checking (by open-ended questioning, reflecting, silence)	x	x	x	x	x	x

14	Empathy/legitimating	x	x	x	x	x	x

15	Making information circulate between participants	 	 	x

16	Being supportive	x	x	x	x	x	x

17	Summarizing	x	x	x	x	x	x

18	Planning the future	x	x	x	x	x	x

19	Remaining calm	 	 	x	 	 	x

20	Checking patient’s understanding at the end	x	x	x	x

21	Non verbal	x	x	x	x	x	x

22	Defining the limits	 	 	x	 	 	x

23	Negotiating a common solution with the patient	 	 	x	 	 	x

24	Maintaining the frame	 	 	 	 	x	x

25	Acknowledging the problem	 	 	 	 	 	x

26	Apologizing	 	 	 	 	 	x

Code	Communication items	Inpatient	Outpatient

		Explaining	Breaking bad news	Discussing with a family	Explaining a diagnosis	Managing time	Managing a difficult consultation

4	Introducing each other			x

5	Negotiating the agenda			x	x	x	x

6	Announcing		x

7	Exploring patient’s perspectives	x	x	x	x	x	x

8	Exploring patient’s understanding of what has happened						x

9	Summarizing the context	x	x	x	x	x	x

10	Informing	x	x	x	x	x	x

11	Clarifying roles, rules			x

12	Using clear language/no jargon	x	x	x	x		x

13	Chunking and checking (by open-ended questioning, reflecting, silence)	x	x	x	x	x	x

14	Empathy/legitimating	x	x	x	x	x	x

15	Making information circulate between participants			x

16	Being supportive	x	x	x	x	x	x

17	Summarizing	x	x	x	x	x	x

18	Planning the future	x	x	x	x	x	x

19	Remaining calm			x			x

20	Checking patient’s understanding at the end	x	x	x	x

21	Non verbal	x	x	x	x	x	x

22	Defining the limits			x			x

23	Negotiating a common solution with the patient			x			x

24	Maintaining the frame					x	x

25	Acknowledging the problem						x

26	Apologizing						x


Histopathology	Pediatrics	Adults	All patients

n (%)

Pineal region tumors	4 (10)	2 (5)	6 (14)

Colloid cyst	-	6 (14)	6 (14)

Pilocytic astrocytoma	3 (10)	2 (5)	5 (12)

Central neurocytoma	1 (2)	4 (10)	5 (12)

Glioblastoma	1 (2)	3 (7)	4 (10)

Atypical teratoid rhabdoid tumor	3 (7)	-	3 (7)

Ependymoma	-	2 (5)	2 (5)

Meningioma	-	2 (5)	2 (5)

Lymphoma	-	1 (2)	1 (2)

Choroid plexus papilloma	1 (2)	-	1 (2)

Anaplastic ependymoma	1 (2)	-	1 (2)

Anaplastic astrocytoma	1 (2)	-	1 (2)

Mature teratoma	1 (2)	-	1 (2)

Anaplastic oligodendroglioma	-	1 (2)	1 (2)

Craniopharyngioma	-	1 (2)	1 (2)

Glioneuronal tumor	1 (2)	-	1 (2)

Langerhans cell histiocytosis	1 (2)	-	1 (2)

Total	18	24	42

Histopathology	Pediatrics	Adults

n (%)

Pineal region tumors	4 (10)	2 (5)

Colloid cyst	-	6 (14)

Pilocytic astrocytoma	3 (10)	2 (5)

Central neurocytoma	1 (2)	4 (10)

Glioblastoma	1 (2)	3 (7)

Atypical teratoid rhabdoid tumor	3 (7)	-

Ependymoma	-	2 (5)

Meningioma	-	2 (5)

Lymphoma	-	1 (2)

Choroid plexus papilloma	1 (2)	-

Anaplastic ependymoma	1 (2)	-

Anaplastic astrocytoma	1 (2)	-

Mature teratoma	1 (2)	-

Anaplastic oligodendroglioma	-	1 (2)

Craniopharyngioma	-	1 (2)

Glioneuronal tumor	1 (2)	-

Langerhans cell histiocytosis	1 (2)	-

Total	18	24


Visual area	Raw N PV	Corrected N PV	Raw N dual-labeled	Corrected N dual-labeled	% dually-labeled

V1	293	205	235	164	80

MT	293	205	218	153	75


Variable	Total of patients or mean value

eight (g)

<750	12 (0,8%)

[750–1000[	14 (0,9%)

[1000–1500[	72 (4,8%)

[1500–2500[	464 (31,1%)

[2500–4000[	881 (59,1%)

≥4000	49 (3,3%)

Mode of delivery

Cesarean section	721 (48,3%)

Vaginal delivery	771 (51,7%)

Mechanical ventilation

Invasive	52 (3,5%)

Noninvasive	45 (3,0%)

Both modalities	151 (10,1%)

Phototherapy	675 (45,2%)

Parenteral nutrition	221 (14,8%)


	Total (£)

Trial Website:

Implementation of the consent process and the randomization and group assignment system	470

Implementation of the primary and secondary outcome questionnaires, including the code	1,410

Basic e-mail reminders system and follow-up questionnaires system	1,645

Control Website:

Implementation of the control site (estimated about 15-20 pages of information)	1,645

Intervention Website:

Implementation of the three modules, based on restructuring some old content and adding more new content provided by research team	5,875

SUB TOTAL:	11,045

Technical consultancy & project management	7,050

AGREED SPEND AT OUTSET:	18,095

VAT @ 17.5%	3,167

TOTAL	21,262


	Acinetobacter baumanii (N = 59)	Escherichia coli (N = 92)	Klebsiella pneumoniae (N = 92)	Pseudomonas aeruginosa (N = 26)	Non-typhoidal Salmonella (N = 20)

Antimicrobial	No isolates tested	No (%) Susceptible	No isolates tested	No (%) Susceptible	No isolates tested	N (%) Susceptible	No isolates tested	N (%) Susceptible	No isolates tested	N (%) Susceptible

Ampicillin	–	–	91	9 (9.9)	92	–	–	–	20	19 (95)

Co-amoxyclava	–	–	89	43 (48.3)	91	27 (29.7)	–	–	1	1 (100)

Ceftriaxone	–	–	90	59 (65.6)	88	20 (22.7)	–	–	20	20 (100)

Ceftazidime	59	24 (40.7)	91	60 (65.9)	91	20 (22)	26	23 (88.5)	1	1 (100)

Ciprofloxacin	59	45 (76.3)	87	70 (80.5)	85	52 (61.2)	26	15 (57.7)	19	18 (94.7)

	Acinetobacter baumanii (N = 59)	Escherichia coli (N = 92)	Klebsiella pneumoniae (N = 92)	Pseudomonas aeruginosa (N = 26)	Non-typhoidal Salmonella (N = 20)

Antimicrobial	No isolates tested	No (%) Susceptible	No isolates tested	No (%) Susceptible	No isolates tested	N (%) Susceptible	No isolates tested	N (%) Susceptible	No isolates tested	N (%) Susceptible

Piperacillin-tazobactam	58	10 (17.2)	6$	5 (83.3)	49$	34 (69.4)	7$	1 (14.3)	1$	1 (100)

Gentamicin	59	27 (45.8)	91	64 (70.3)	89	25 (28.1)	25	15 (60)	–	–

Amikacin	58	26 (44.8)	92	77 (83.7)	91	70 (76.9)	26	16 (61.5)	–	–

Meropenem	56	26 (46.4)	92	92 (100)	92	92 (100)	26	22 (84.6)	20	20 (100)

Imipenem	49	27 (55.1)	90	90 (100)	90	90 (100)	26	21 (80.8)	20	20 (100)

Ertapenem			92	92 (100)	91	91 (100)	–	–	20	20 (100)

Colistin	59	59 (100)	90	90 (100)	89	89 (100)	26	23 (88.5)	–	–


Parameter	HR point estimate	95% CI	p-value

Continuous variables

Age (years)*	1.05	0.81-1.37	0.722

Gleason score	0.82	0.71-0.96	0.012

PSA#	1.00	0.89-1.13	0.001

Linear interaction term with time°	1.03	1.01-1.06

ALP#	1.07	0.99-1.16	0.074

LDH#	1.22	1.02-1.46	0.027

Categorical variables

Staging at diagnosis

 M0	1

 M1	0.92	0.59-1.45	0.733

Metastatic sites

 Bone only	1

 Other	0.80	0.40-1.59	0.526

Parameter	HR point estimate	95% CI	p-value

PSA#	1.00	0.89-1.13	0.001

Linear interaction term with time°	1.03	1.01-1.06

ALP#	1.07	0.99-1.16	0.074

LDH#	1.22	1.02-1.46	0.027

Categorical variables

Staging at diagnosis

M0	1

M1	0.92	0.59-1.45	0.733

Metastatic sites

Bone only	1

Other	0.80	0.40-1.59	0.526


Statement	Online simulator superior	Equivalent	Atlas or lecture superior	Unsure

Learning tympanic membrane anatomy	45.5%	45.5%	0.0%	9.1%

Learning external auditory canal anatomy	63.6%	36.4%	0.0%	0.0%

Learning otoscopy technique	63.6%	27.3%	0.0%	9.1%

Availability of training technique	54.5%	9.1%	27.3%	9.1%

Statement	Online simulator superior	Equivalent	Atlas or lecture superior	Unsure

Learning tympanic membrane anatomy	45.5%	45.5%	0.0%	9.1%

Learning external auditory canal anatomy	63.6%	36.4%	0.0%	0.0%

Learning otoscopy techn	63.6%			9.1%

Statement	Online simulator superior	Equivalent	Atlas or lecture superior	Unsure

ique		27.3%	0.0%

Availability of training technique	54.5%	9.1%	27.3%	9.1%


LncRNA name	Target	Cell type	Organism/system

FAL1	p21	Cancer cells	Human/in vitro

BANCR	p21	Colorectal cancer cells	Human/in vitro

LINCRNA-p21	p21	Mouse embryonic fibroblasts	Mouse/in vivo and in vitro

MALAT1	p53	Human osteosarcoma cells	Human/in vitro

7SL	p53	HeLa cells	Human/in vitro

VAD	INK4 locus/p16INK4a	hTERT-immortalized WI38 human fibroblasts	Human/in vitro

ANRIL	INK4 locus/p16INK4a	WI38 cell line	Human/in vitro

MIR31HG	INK4 locus/p16INK4a	Immortalized human diploid fibroblasts, TIG3-hTERT	Human/in vitro

UCA1	p16INK4a mRNA	Mouse primary cells	Mouse/in vitro

SAL-RNA	p53	WI38 cell line (old versus young)	Human/in vitro

SALNR	NF-90 localization	Human fibroblast cells	Human/in vitro

TERRA	Telomere length	Mammalian cells and medulloblastoma

ASNCMTRNA2	hsa-miR-4485	Human endothelial cells	Human/in vitro

HOTAIR	E3 ubiquitin ligase and PRC2	Ovarian cancer cells and HeLa cells	Human/in vitro

PANDA	PRC1 and PRC2 recruitment	Primary human diploid fibroblast strains, BJ (neonatal foreskin), and WI38 (fetal lung)	Human/in vitro

LncRNA name

FAL1

BANCR

LINCRNA-p21

MALAT1

7SL

VAD

ANRIL

MIR31HG

UCA1

SAL-RNA

SALNR

TERRA

ASNCMTRNA2

HOTAIR

PANDA

Target	Cell type	Organism/system

p21	Cancer cells	Human/in vitro

p21	Colorectal cancer cells	Human/in vitro

p21	Mouse embryonic fibroblasts	Mouse/in vivo and in vitro

p53	Human osteosarcoma cells	Human/in vitro

p53	HeLa cells	Human/in vitro

INK4 locus/p16INK4a	hTERT-immortalized WI38 human fibroblasts	Human/in vitro

INK4 locus/p16INK4a	WI38 cell line	Human/in vitro

INK4 locus/p16INK4a	Immortalized human diploid fibroblasts, TIG3-hTERT	Human/in vitro

p16INK4a mRNA	Mouse primary cells	Mouse/in vitro

p53	WI38 cell line (old versus young)	Human/in vitro

NF-90 localization	Human fibroblast cells	Human/in vitro

Telomere length	Mammalian cells and medulloblastoma

hsa-miR-4485	Human endothelial cells	Human/in vitro

E3 ubiquitin ligase and PRC2	Ovarian cancer cells and HeLa cells	Human/in vitro

PRC1 and PRC2 recruitment	Primary human diploid fibroblast strains, BJ (neonatal foreskin), and WI38 (fetal lung)	Human/in vitro


		Proportion of reps. meeting:

		Linkage threshold	Association threshold (avg. no. SNPs analyzed)c	Avg. no. cases analyzed	Overall power

		Stringenta	Looseb	Stringent	Loose	Stringent	Loose	Stringent	Loose

9 (186)	A	0	0.14	0 (n/a)	0 (144)	1500	1500	0	0

	B	0	0.14	0 (n/a)	0 (144)	983	987	0	0

	C	0.13	0.64	0.23 (48)	0.25 (145)	127	136	0.03	0.16

	D	0.83	0.96	0.01 (48)	0 (147)	1500	1500	0.01	0


Characteristic

Age, years	69.6 ± 17.0a

Male sex, no. (%)	187 (61.9)

Smoking status

 Current smoker, no. (%)	73 (24.2)

 Pack-years for smokers	40.1 ± 24.2a

Antibiotic pretreatment (%)	61 (20.2)

Coexisting illnesses, no. (%)

 Coronary artery disease	97 (32.1)

 Hypertensive heart disease	78 (25.8)

 Congestive heart failure	16 (5.3)

 Peripheral vascular disease	20 (6.6)

 Cerebrovascular disease	16 (5.3)

 Renal dysfunction	81 (26.8)

 Liver disease	31 (10.3)

 Diabetes mellitus	61 (20.2)

 Chronic obstructive pulmonary disease	76 (25.2)

 Neoplastic disease	48 (15.9)

History, no. (%)

 Cough	270 (89.4)

 Sputum	221 (73.2)

 Dyspnea	229 (75.8)

Examination, no. (%)

 Rales	271 (89.7)

Laboratory findings

 CRP (mg/l), median (IQ range)	129.7 [65–211]

 Procalcitonin (μg/l), median (IQ range)	0.5 [0.2–2.2]

 Leukocyte count (× 109)	13.6 ± 6.7a

 proADM (pmol/l), median (IQ range)	1.1 [0.6–1.9]

Radiographic findings, no. (%)

 Pleural effusion	37 (12.3)

 Multilobar CAP	53 (17.5)

PSI points	99.4 ± 35.3a

PSI class, no. (%)

 I, II and III	120 (39.7)

 IV	130 (43)

 V	52 (17)


Plants	Root number (mean ± SE)a	Root length (cm) (mean ± SE)b	Dry root biomass (mg) (mean ± SE)b	Shoot height (cm) (mean ± SE)b	Dry shoot biomass (mg) (mean ± SE)b

WT	4	28.2 ± 0	543.6 ± 14	4	3093.4 ± 146.


Gene Symbol	Gene Name	Entrez Gene ID	Fold difference DA/Cia5a	p-value*

 	Anti-inflammatory and regulators of immune responses

Scd1	stearoyl-Coenzyme A desaturase 1	246074	54.62	0.0001

Timp3	TIMP metallopeptidase inhibitor 3	25358	11.48	0.000000003

Adipoq	adiponectin, C1Q and collagen domain containing	246253	10.96	0.000003

Ptpn11	protein tyrosine phosphatase, non-receptor type 11	25622	4.18	0.00002

Cyp2j3	cytochrome P450, family 2, subfamily j, polypeptide 3	313375	3.38	0.002

Ptgis	prostaglandin I2 (prostacyclin) synthase	25527	2.63	0.0003

Cat	catalase	24248	1.91	0.002

Gss	glutathione synthetase	25458	1.56	0.001

Sod1	superoxide dismutase 1, soluble	24786	1.53	0.00002

 	Nuclear receptors and an interacting protein

Rxrg	retinoid X receptor gamma, Nr2b3	83574	5.39	0.0001

Pparg	peroxisome proliferator-activated receptor gamma, Nr1c3	25664	5.32	0.00005

Rev-erba	Nr1d1	252917	3.41	0.004

Arp1	Nr2f2	113984	2.45	0.0002

Nrip1	nuclear receptor interacting protein 1	304157	2.35	0.00004

Thrb	thyroid hormone receptor beta, Nr1a2	24831	2.07	0.002

Thra	thyroid hormone receptor alpha, Nr1a1	81812	1.97	0.001

Ncor1	nuclear receptor co-repressor 1	54299	1.89	0.003

Rora	RAR-related orphan receptor alpha, Nr1f1	300807	1.88	0.0001

Lxra	Liver X receptor alpha, Nr1h3	58852	1.52	0.0006

Gene Symbol	Gene Name	Entrez Gene ID

	Anti-inflammatory and regulators of immune responses

Scd1	stearoyl-Coenzyme A desaturase 1	246074

Timp3	TIMP metallopeptidase inhibitor 3	25358

Adipoq	adiponectin, C1Q and collagen domain containing	246253

Ptpn11	protein tyrosine phosphatase, non-receptor type 11	25622

Cyp2j3	cytochrome P450, family 2, subfamily j, polypeptide 3	313375

Ptgis	prostaglandin I2 (prostacyclin) synthase	25527

Cat	catalase	24248

Gss	glutathione synthetase	25458

Sod1	superoxide dismutase 1, soluble	24786

	Nuclear receptors and an interacting protein

Rxrg	retinoid X receptor gamma, Nr2b3	83574

Pparg	peroxisome proliferator-activated receptor gamma, Nr1c3	25664

Rev-erba	Nr1d1	252917

Arp1	Nr2f2	113984

Nrip1	nuclear receptor interacting protein 1	304157

Thrb	thyroid hormone receptor beta, Nr1a2	24831

Thra	thyroid hormone receptor alpha, Nr1a1	81812

Ncor1	nuclear receptor co-repressor 1	54299

Rora	RAR-related orphan receptor alpha, Nr1f1	300807

Lxra	Liver X receptor alpha, Nr1h3	58852


Variable	Frequency	Median (IQR) or percentage

Age in years	740	35 [27–42]

Age group

 ≥45 years	156	21.1

 <45 years	584	78.9

Sex

 Male	275	37.2

 Female	465	62.8

Marital status

 Married	278	37.6

 Divorced	160	21.6

 Widow	154	20.8

 Single	51	6.9

WHO stage

 3 & 4	261	35.3

 1 & 2	479	64.7

Baseline CD4 (cell/μl)	740	256 [132–469]

Baseline CD4 group

 ≤200 cell/μl	258	34.9

 >200 cell/μl	482	65.1

Hemoglobin (g/dL)	740	11.4 [9.7–13.1]

Normal HB	452	61.1

Anemia total	288	38.9

 Mild anemia	147	19.9

 Moderate anemia	88	11.9

 Severe anemia	53	7.2

OI on diagnosis

 Tuberculosis	197	26.6

 Others	543	73.4

Outcome on ART

 Median time (Mo)	740	27 [17–37]

 Dead	86	11.6

 Alive	654	88.4

Variable	Frequency	Median (IQR) or percentage

Moderate anemia	88	11.9

Severe anemia	53	7.2

OI on diagnosis

Tuberculosis	197	26.6

Others	543	73.4

Outcome on ART

Median time (Mo)	740	27 [17–37]

Dead	86	11.6

Alive	654	88.4